Predicting the carcinogenicity of chemicals in humans from rodent bioassay data. by Goodman, G & Wilson, R
EnvironmentalHealth Perspectives
Vol. 94, pp. 195-218, 1991
Predicting the Carcinogenicity of
Chemicals in Humans from Rodent
Bioassay Data
by Gay Goodman*" and Richard Wilson*
Regulatoryagenciescurrentlyrelyonrodentcarcinogenicity bioassaydatatopredictwhetherornotagivenchemical
posesacarcinogenicthreattohumans. Wearguethatitisalwaysmoreuseful toknowachemical'scarcinogenic potency
(with confidence limits) than to be able tosay only qualitatively that it has been found to be acarcinogen. In atypical
bioassay, achemical isadministered togroupsof50to 100rodents atthehighestfeasiblelevel (themaximum tolerated
dose)andrarelyatlessthan 1/10thisdoseinordertomaximizethestatisticalsignificanceofanyincreaseintumorsthat
mightresult.Recently, muchexperimental workhasfocusedonthemechani bywhichsite-specifictoxicityarisingfrom
chronicadministration atthemaximumtolerateddosemayleadtocarcinogencity. Extrapolationofhigh-doseresultsto
lowdosesdoesnottakeintoconsiderationthepossibilityofathresholddose,belowwhichthecarcuiogenicpotencyismuch
lowerorevenzero. Thresholddose-response phenomenamaybemuch morerelevanttotheetiologyofcancerinthero-
dent bioassays than was earlier realized; ifso, there is an even greater need for establishing dose-dependent potency
estimates. Theemphasisofthisreviewisontheinterspeciescomparisonofhigh-dosepotencies. Thequalitative andquan-
titativecomparisonofcarcinogenicitiesbetweenmiceandrtsandbetweenrodentsandhumansisreviewedanddiscussed.
Weconcludethatthereisagoodqualitative (yes/no)correlationforboththerat/mouseandtherodent/humancomparison.
Thereisalsoagoodcorrelation ofthecarcinogenic potenciesbetween ratsandmice, andtheupperlimitson potencies
inhumansareconsistentwithrodentpotenciesforthosechemicalsforwhichhumanexposuredataareavailable. Forthe
rodent/humancomparison, thebestestimateoftheinterspecies potencyfactorislognormallydistributedaround 1 when
the potencies inbothspecies are measured in unitsof(mg/kg-day) -'.
Introduction
Wheneverresearchers havethoughtthatthere is asimplifying
featureaboutcancer, furtherstudies havearrived todemonstrate
complications. This particularly applies to any attempts to
develop rules fordiscovering potentialhumancarcinogensand
forestablishing low-risk exposure limits. Ofcourse, wedo not
deliberately expose people to a chemical merely to find out
whether it causes cancer; human epidemiological information
comes from accidental, incidental, or therapeutic exposures.
Thisforces us tosearchforothermethodsofpredicting whether
achemical iscarcinogenic tohumans. Althoughthedevelopment
ofshort-termin vitroandin viw testsholdspromiseforthefuture
inpredicting thecarcinogenicity ofsubstances, atthe very least
we are left with the task of interpreting the existing rodent
bioassaydata. Theproblemthenbecomes: howshould weutilize
the results of carcinogenicity tests in rodents for predicting
cancer risk inhumans?
In long-term bioassays, chemicals are tested at the highest
possible doseinordertomaximize thesensitivity fordetecting
carcinogenic effects. To take a hypothetical example, if a car-
cinogen induces a particular type ofneoplasm with frequency
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0.2 atdosedand with frequency 0.02 when the dose is (1/10)d,
theninatestof100animalsthecarcinogenicity ofthechemical
wouldbedetectableabovebackgroundatthehigherbutnotthe
lowerdose. Themaximumdosetested(MaxD) isusually setat
themaximumtolerated dose(MTD), thehighestdosethatdoes
not cause death, organ toxicity, or severe weight loss during a
chronic dosing regime ofseveral months' duration. The other
dosesinthebioassayareusuallychosenas somefractionofthe
MTD, andareonlyrarelyassmallorsmallerthanMTD/10. One
issuesurroundingthefactthatthebioassaysareconductedathigh
dosesisthattheshapeofthedose-responsecurveatmuchlower
dosesisnotnecessarily predictedbythedose-response nearthe
MTD. Although wereturntothispointwhendiscussingpossi-
ble mechanisms ofchemical carcinogenesis, the high-dose to
low-doseextrapolation isnotthesubjectofthisreview. Itis im-
portant to acknowledge that there are two separate aspects of
determining human risk from data taken in rodent bioassays,
namely a) the high-dose/low-dose extrapolation andb) the in-
terspeciesextrapolationofhigh-dosepotencies. Weemphasize
thathereweareaddressingmainlythe secondaspect, inwhich
carcinogenic potencies obtained in rodents are used to predict
potencies inhumans exposed at similarly high doses.
Which ChemicalsAre Carcinogens?
Twenty years ago, there were not many agents that wereGOODMANAND WILSON
known to cause cancer in either laboratory animals or man. It
wasconsidered prudenttoimpose strictregulatory restrictions
ontheuseofallsuchchemicals. Itwasgenerallyanticipatedthat
fewnewcarcinogenswouldbediscovered; certainlythepercent-
age of chemicals tested for carcinogenicity that turned up
"positive" waslowatthattime. Inonestudyof120pesticidesand
industrial chemicals givenorally for 18monthsattheMTD, only
11 ofthechemicalstested(9%)causedcancerinmice(1). This
oft-quoted study has beencited as evidencethatchemicals can
begivenatnear-toxic doseswithoutautomaticallytrigeringcar-
cinogenicity secondary totoxic effects (2). Although we agree
for other reasons (see above) that it is reasonable to test at the
MTD, theresultsofInnesetal. (1)bearfurtheranalysis. Infact,
amongthe 109chemicalsnotfoundtobecarcinogenic, 20(17%)
wereconsideredbytheauthorstorequirefurtherinvestigation.
AmesandGold(3) statedthatthis study waslessthorough than
modern protocols and pointed out that only one species was
tested. Wealso notethatevenwiththeidenticalprotocol, some
additional chemicals would mostlikelyhaveproducedtumorsif
thedurationofexposure orevenobservationhadbeenextended
to 24 months.
In the intervening years, the available information has in-
creased. We now know ofhundredsofchemicalsthatcancause
cancerinanimals; manyareimpossibletoban, andsomeareof
naturalorigin(4). Newcancerbioassaysinvolvedosinganimals
daily for aperiod ontheorderofalifetime: 2 yearsfor ratsand
mice. Moreanimals areused, both sexesoftwo species areex-
posed, generallyhigherdoses areadministered, andtheeffects
atseveral doselevels(usually atleastthree)areincluded(5). Of
266chemicals consideredtohavebeenadequatelytestedin rats
and mice ofboth sexes at or nearthe MTD in 2-yearprotocols
by the National Toxicology Program (NTP) and the National
Cancer Institute (NCI), 51% percent were found tobepositive
forcarcinogenicity in atleastonesex-speciesgroup; theevalua-
tionofpositivity wasaccording totheconclusions stated inthe
NCI/NTP Technical Reports (6,7).
Almostthesamedatahasbeenlookedatinaslightlydifferent
waybyByrdetal. (8). Giventhatallexperimentsconsistedofat
leasttwodosegroupsandonecontrolgroup, theircriterionfor
positivity was an increased site-specific tumor incidence with
p < 0.025 foranindividualdosegroup, orp < 0.05 foranytwo
dose groups (if one or both failed to meet the more stringent
criterion), by Fisher exact test. Outofa total of290 chemicals
testedbytheNCI/NTPandincludedontheirCarcinogenicBio-
assay DatabaseSystem (CBDS)magnetictapes asofDecember,
1987, 50% werepositiveinmice, 52% werepositivein rats, and
71% werepositiveinatleastonesex-speciesgroup. Ifthetumor-
bearingmaleandfemaleanimals werecombinedbeforetesting
for statistical significance, then the fraction labeled positive
wouldbe greater still. We notealsothatbecausethenumberof
animals perdose group is usually 50 or 100, tumor incidences
belowthelevelof5% may gounobserved orbe discounteddue
tolackofstatistical significance. Ifthesensitivity wereimproved,
forexample,byusing 1000animalsperdosegroup, manymore
chemicalsmightbeshowntobecarcinogenic. However, sincethe
statistical criteria forpositivity usedby Byrd etal. were rather
liberal(8), itislikelythatmanyofthestatisticallysignificantdif-
ferencesin tumorincidencewerefalsepositives, reflectingmere-
ly random variability (9-11).
Along with an increase in the power ofanimal tests to iden-
tify carcinogenic substances, there has been a parallel im-
provement in the methodology for detecting trace amounts of
chemicals. Thirty years ago, an upper limit on sensitivity of
a few parts per million was common. It seemed likely that any
carcinogen found in foodstuffs at that level would pose a
significant risk and remedial action should be demanded. So
few chemicals in commercial use were known to be car-
cinogens that it seemed that they could be avoided and replac-
ed by alternatives. This was the rationale that led to the inclu-
sion ofthe Delaney Clause in the Food Additive Amendments
of 1958 [reviewed by Hutt (12)]. If a few turned out to be
essential or in unusual demand, then special legislation could
be enacted, as later happened for saccharin. But we can now
detect trace contaminant levels to one part in 1012 in some
cases. As a result, in typical drinking water supplies, at least
20 chemicals known to be rodent carcinogens are well above
the detection level, and many other chemicals are present for
which information as to carcinogenicity is either unavailable
or inadequate. Because we find it technically or economical-
ly unfeasible to remove all such chemicals from our drinking
water, our diet, and the environment in general, it becomes
necessary to rank chemicals according to the risk they are ex-
pected to pose to human health. One means ofachieving such
a ranking is by measuring carcinogenic potencies in animals
and finding some means of extrapolating these results quan-
titatively to humans.
It seems therefore unhelpful to classify chemicals as car-
cinogensornoncarcinogens, buttoassumethatallchemicalsare
carcinogenicandthatsomehavetoolowapotencytoproducea
statistically significant increase in tumors with a given ex-
perimental protocol. This is a variation on a statement by
Paracelsus: "Allthingsarepoisons, forthereisnothingwithout
poisonous qualities. It is only the dose which makes a thing a
poison." [quotedbytheScientificCommitteeoftheFoodSafety
Council (13)]. Underthis scheme, achemical thatistruly non-
carcinogenicatanydoseis aspecial caseandwouldbecalled a
carcinogen ofzero potency.
The assumption that all chemicals may be carcinogenic only
leads to a useful procedure if one can determine the quan-
titative carcinogenic potency for each chemical and an upper
limit to the potency in cases where the potency is too low to
be detected. In the present paper we review the work of our
group and of others on the interspecies correlation of car-
cinogenic potencies, particularly between mice and rats. Fur-
ther analysis is provided of the methodology, efficacy, and
limitations for the use of rodent bioassay data in predicting
human carcinogenic potencies. Gregory (14) and Dybing (15)
have recently reviewed interspecies comparisons with respect
to predicting carcinogenic risk in humans; we have attempted
not to duplicate their efforts, and the reader is refered to these
papers for alternative points of view.
Quantitation: Relating Carcinogenic
Potencyto Other Parameters
Currently, thereexists nogoodalternativetoanimalbioassays
forobtainingquantitativeinformationonthecarcinogenicpoten-
tial ofchemicals inany species. Theanimalbioassaydatabase
containsinformationonthetumorigeniceffectsofalmost 1000
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chemicals. Althoughmanychemicalshavebeentestedfortheir
abilitytoinducepointmutations inSalmonellastrains, andsome
havebeenassayedforothergenotoxic,cytotoxic, orpreneoplastic
effects inavariety ofshort-termin vitroandin vivotests, aquan-
titativemethodthatbeginswithdataderivedfromsuchtestsand
endswithaprediction ofcarcinogenic potency inhumanshasnot
yet been put forward. As knowledge ofthe molecular mechan-
isms ofaction ofgenotoxic carcinogens increases, short-term
testsforgenotoxicity shouldbedesignedtoreflecttheimportance
ofdifferent genetic end points in primary carcinogenesis (16).
Research into the mechanisms of action of nongenotoxic car-
cinogens, along with novel experiments todetermine theirlikely
importance in animals or humans when moderate levels ofen-
dogenous orenvironmental initiators arepresent simultaneously,
should point the way toward development of yet another gen-
eration of short-term tests. For example,knowledge that the
tumorpromotingactionof12-O-tetradecanoylphorbol-13-acetate
(TPA) is mediated by activation ofprotein kinase C, which is a
key component oftransmembrane signal transduction relevant
to the regulation of cell division, suggests that other tumor
promoters might function by disrupting the same or related
pathways ofsignaltransduction (17). Itis conceivable thata sim-
ple in vitro test for promoters having such activity could be
designed (18).
Althoughthereis goodreasontobeoptimistic thatshort-term
tests will someday providethemeans forpredicting the potency
ofhuman carcinogens, thatday has notyetarrived (19). Itis clear
that positivity on short-term tests for genotoxicity is highly cor-
related with carcinogenicity for the known human carcinogens:
ofthe23chemicalsandchemicalcombinations designatedbythe
International Agency for Research on Cancer ([ARC) to be
causally associated withhumancancer, allbuttwo (asbestos and
conjugated estrogens) aregenotoxic orareexpected tobe soon
thebasis ofchemical structure (20). Butbecauseofthepaucity
ofdataonhumancarcinogenicity andondefinitivehumannon-
carcinogens, there is only avery limited opportunity forattemp-
ting to calibrate short-term test results to these data. The em-
phasis has thus beenondemonstrating agreementbetween short-
term tests and rodent carcinogenicity bioassays, both qualitative
(21-25) and quantitative (26-30). When the specificity ofex-
isting short-term tests atdistinguishing between rodent noncar-
cinogens andcarcinogens is analyzed, theirpoweras predictive
tools is less impressive than when sensitivity to rodent car-
cinogens is the only criterion (31,32). The finding that a large
proportion ofknown rodent carcinogens are not genotoxic in
short-term tests (23) underscores the necessity of developing
short-term tests fornongenotoxic carcinogens. Sincetheanalysis
oftheefficacy ofall short-term tests isfocusedprimarily on ex-
isting carcinogenicity dataobtained inlong-termanimal studies,
itis important totry and ascertain thebestmethods for retriev-
ing information relevanttohumancarcinogenic potency from the
bioassay data andto quantify theexpecteduncertaintyin both the
upper and lower bounds ofsuch potency estimates.
Dose Conventions
Before testing forcarcinogenicity wasevencontemplated, the
testing of chemicals for toxic effects in animals was used for
predicting toxic effects in humans. There are several ways to
formulate the dosage administered for the purposes of such a
comparison; seeCalabrese(33)foracomprehensivereview. The
usual convention for normalizing dose is on a weight/weight
basis; weightofthechemicaldividedbytheweightoftheanimal.
Thereportingofdoseasafractionofbodyweightdoesnotim-
plythatequaleffectswillbeproducedintwospeciesifthedosage
isscaledaccording totheirweights. Itismerelyaconventionand
nomore. However, this convention aroseoutofanexpectation
thattheamountofchemical (expressedasaweight)whrequired
toachievethesametoxiceffectintheheavieranimalthatispro-
ducedinthelighteranimalbytheamountw,iswn =w,(W.1 ),
where Whand W are the weights of the heavier and lighter
animals, respectively. Acrudesurfaceareacorrectionissome-
timesappliedtotheusualdoseconvention, suchthatthepredic-
tionforequaltoxicity becomes wh =w,(Whl )92A . Ifinsteadof
theweightofchemicalwenowusetheconventioninwhichdose
is normalizedonaweight/weightbasis, i.e., dosed = w/l Wthen
the surface-area-corrected prediction for equal toxicities
becomesd = ,(W^/ W)'k Anexcellentinterspecies correlation
of minimal toxic doses was found for a series of 18 chemo-
therapeutic agents when the scaling factor was based on body
surface area (34). It was later realized that these chemicals are
notreadily metabolized by livermicrosomal enzymes, andthus
interspecies variation in such metabolism was not amajor fac-
tor in thecomparison (35). Calabrese (33)concludes thatin the
absence ofanefficient drug-metabolizing system, adrug's tox-
ic effects are similar among species when the dose is scaledon
thebasisofsurfacearea. However, anotherstudyoftheacutetox-
icity of 400 chemicals revealed a good correlation with body
weight(andnotbodyweighttothe2/3 power) formorethan 80%
ofthe chemicals (36). One might expect that for all chemicals
within agiven chemical class, the samedose convention would
be appropriate to the interspecies comparison oftoxic effects.
Forcarcinogenic potency, thereexistsasimilaruncertainty as
towhichdoseconvention touse to simplify the interspecies com-
parison. Inaddition, sincecancertypically develops as a result
oflong-term exposure to acarcinogenic substance, the factorof
time enters thedetermination ofpotency. With daily administra-
tion, a steady-state coficentration of the active agent in the
animal's system is approached. There is no obvious reason that
the same interspecies scaling factor shouldapply here as is rele-
vant to acute effects such as the response to a single dose ofa
drug. In the present paper, for simplicity, we refer to the daily
doseadministered onaweight/weightbasis (typically milligrams
perkilogram) forthelifetimeoftheanimal orhuman. Useofthis
convention, by analogy withthatdescribed above foracute tox-
icity, does not imply that weight scaling always produces a 1:1
correspondence between effective carcinogenic doses in two
species. Forexample, B6C3F1 mice andF344 ratsdemonstrated
abettercorrelation ofcarcinogenic potencies with surface area
scalingthan withweight scaling, butforthe same(B6C3FJ)mice
strain and a different (Osborne-Mendel) rat strain the opposite
wastrue: weight scalingyielded ahigherdegree ofpotency cor-
relation than did surface area scaling (37). Based upon recent
workonphysiological parameters controlling pharmacokinetics,
Travis etal. have suggested that the optimum interspecies scal-
ing factor (for this chemical and this organ) is in fact closer to
weight to the UA power (38). We consider that the best estimate
foraninterspeciesscalingfactorisanunknown, tobedetermined
from existing data. In the risk-assessment procedure the most
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accurate scaling factor ought, in principal, to be adopted on a
case-by-case basis; unfortunately, relevantinformation isonly
rarely available.
Indexes ofCarcinogenic Potency
Thedatafromlong-termbioassayscanbeanalyzedaccording
toany one ofa number ofdose-responsemodels resulting, for
each experiment, in a measure ofthe chemical's carcinogenic
potency. Onestandardindexofcarcinogenicpotency,is(3, which
herewetaketobetheslopeofthedose-responserelationshipat
the dose ofinterest (37,39). In principle, the potency can be a
functionofdosed: (3 = R(d). Inthelimitwhere(3 isconstant, a
formulacanbederivedforthefractionalprobabilityPofproduc-
ing at least onetumorat agiven site:
P(d) = -(1-o) Io p(e- ) (1)
where et is the background rate ofanimals with tumors atthat
site. This formulawasspecificallyconstructedtoreachbutnot
exceedP = 1 athighdosesandtohavethe(linear)low-doselimit
P = ca + (d, whichmeansthat( istheinitial slopeofPversus
d (39). The model was orginally derived in terms of tumor-
bearinganimalsratherthananimalswithtumorsataspecificsite,
but the form is the same ineithercase.
Useful bioassay data fall approximately inthe rangeof 10 to
95% tumor incidence at the most sensitive site. Gold and co-
workershavechosenanexpressionforpotencythatemphasizes
the region where data are available. Their index ofpotency is
1/TD50, whereTD50isdefinedasthedosethat, ifadministered
daily forthe "standardlifespan" ofthespecies, "willhalvethe
mortality-corrected estimate of the probability of remaining
tumorless[atagivensite]thrughoutthatperiod" (40). Toderive
thisindex, theyusedamathematicalmodelwhich, likeEq. (1),
assumes linearity atlowdoses. Indeed, intheabsenceofinter-
currentmortality(i.e.,deathsduringthetermofthestudy),the
parameter(3 isequivalentto(hn2)/TD50(40). Because I/TD50is
definedintermsofadose, theTD50,whichfallsinthemiddleof
the range forwhich thereareusefuldata, is fairlyindependent
ofthemodelusedinitsderivation. InmostcasestheTD50turns
out to be close in value to the maximum administered dose,
which approximates the MTD (41-43).
Extrapolation from High-Dose to
Low-Dose Potencies
A majorproblem withtesting atdoses neartheMTD isthat
some toxic effects may be inevitable. Chemicals that are car-
cinogeniconly asaresultoftarget-organtoxicitymightexhibit
adose-responserelationshipthatreflectsthesecondary nature
oftheircarcinogenicity. Sincetoxiceffectsusuallyappearonly
aboveathresholddose, onemightanticipatethatsuchsecondary
carcinogens woulddemonstrate asimilarthresholdbehaviorfor
tumorigenicity. Otherchemicalsmightbeprimarycarcinogens,
and it is generally assumed that they would have some quan-
tifiable carcinogenic potential at any dose. Given that such a
distinctionismeaningfil,bothclassesofanimalcarcinogensare
likelytoberelevantinprincipletohumancancer, evenifonlythe
primary carcinogens produce cancer atlow exposure levels in
humans. (We operationally define a "low" dose of a given
substanceratherloosely: adosethatismuchlessthantheMTD
forthatsubstanceinthe speciesbeing addressed.)
Whenattemptingtoextrapolatefromahigh-dosemeasureof
potency (suchas(lor1/TD50)toalow-dosepotency, thechoice
ofdose-response modelbecomescrucialandcanshifttheout-
comebymanyordersofmagnitude. Insomesensethen, useof
anindexofcarcinogenicpotencythatonlyreflectsexperiment-
allymeasurable(high-dose)effectspermitsonetobegtheques-
tionofthevalidity ofany given method forextrapolating from
hightolowdoses. Weareawarethatthereisnosinglecorrectway
to determine low-dose potencies. The problem becomes a
seriousoneincaseswherethereexistsathresholddoseforcar-
cinogenicity. Butformostifnotallgenotoxic carcinogens that
havebeentestedadequately atlowdoses, alow-dosethreshold
has not been found. For such chemicals, the assumption ofa
linear dose response down to zero dose provides a reasonable
estimateofthepotencyatlow doses forthe mostsensitive site.
Examplesare2-acetylaminofluorene(44,45), diethylnitrosamine
anddimethylnitrosamine (46), andN-butyl-N-(4-hydroxybutyl)-
nitrosamine (47).
There is a now a substantial amount ofevidence from ani-
mal experiments indicating that cell proliferation is some-
times associated with the process ofchemical carcinogenesis
when chemicals are administered at doses near the MTD. The
degree oflocal cell proliferation is apparendy a good index for
cell killing; indeed, it has been suggested by Swenberg (48)
that, whereas the MTD as currently determined often results
in a 20-fold increase in cell proliferation in some organ, the
MTD ought to be redefined as that dose which results in no
more than a 3- or 4-fold increase in cell proliferation in any
organ.
The possibility now exists that threshold phenomena for car-
cinogenicity may be explained by increased cell proliferation.
In rats given 2-acetylaminofluorine (2-AAF), which has a
hockey-stick-shaped dose response for mouse bladder tumors
with the number oftumors increasing sharply above 60 ppm,
bladder hyperplasia also increases nonlinearly above60ppm
(49). Similarly, investigationofthetumorigenicityofsaccharin
revealedthatthethresholddoseforbladdertumors inthemale
ratisexplainedbythedose-responseforprecipitationofsilicates
intheurine; female ratsdonotformthesesilicatesinresponse
tosaccharinandarelikewisenotinducedtoformbladdertumors
(49). Apossibleimplicationoffindingssuchastheseisthatfor
chemicalsthatproducetumorsinagivenorganbyamechanism
unrelated to genotoxicity (as evidenced by failure to produce
genotoxiceffectsinshort-termtestsandeitherabsenceofDNA
adductformationinthetargetorganorathresholdresponsefor
tumorigenesis thatdoesnotmatchthedose-response forDNA
adduction), induction ofcell proliferation may be anecessary
conditionfortumorigenesis. Butwhatwedonotyetknowwith
certaintyiswhethertheisolatedcasesinwhichthedose-response
forcellproliferationhasbeenmeasuredisindicativeofthepat-
ternonewouldfindformostorallnongenotoxicchemicals: i.e.,
thatthereisathresholddosebelowwhichachemicalproduces
neither cellproliferation norneoplastic growth. Itis vital that
suchdose-responseinformationbeforthcomingifwearetogain
anymeasureofconfidenceinourability topredictcarcinogenic
potenciesbased oncellproliferation studies.
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Itisalso farfromcertainthatmostgenotoxic agentsthatcause
cancerdo soviagenotoxicmechanisms, eitherinrodents orin
humans. We have reported elsewhere that the carcinogenic
potency (asobtained fromthe rodentbioassay) is more strong-
ly related to the MTD for nonmutagens than for mutagens,
althoughthedifferences aresmall(50). Ourfindings areconsis-
tent with the hypothesis that, even for most mutagens, at high
dosescarcinogenicity isinducedviamechanismsassociatedwith
toxicity. Similarly, for genotoxic chemicals known to cause
cancerinhumans, mostepidemiological evidence comes from
high-dose exposures, approachingtheMTDin many cases. Pro-
bably the best-studied human carcinogen is tobacco smoke,
whichproduces acutetoxic effects inthe lungs andrespiratory
systematalllevelsofusage. Itmaybearguedthatthetargettissue
doselevelishighforthedurationof inhalation, regardlessofhow
few orhow manycigarettes aresmokedperday. Forthis reason,
toxiceffects cannotberuled out as acontributing cause or even
asthemain causeofsmoking-relatedcarcinogenesis, despitethe
factthatcigarette smoke contains potent genotoxins.
Although we have touched briefly upon the low-dose extra-
polationproblem, itisnotthesubjectofthepresentpaper. Readers
arereferredtothereviewofZeiseetal. (51)forathoroughdiscus-
sion ofdose response based on available low-dose data. In the
following, interspeciescomparisonsreferprimarilytopotencies
obtainedwhenthe exposuredoses were athigh orintermediate
levelsforeachofthespeciesunderconsideration.
InterspeciesConversion Factor
In this review, we extrapolate the potency from species a to
speciesbviatherelation 3b = K1j3a(52). Thisequationdefines
the factorKb., which is termed aninterspecies conversion fac-
tor. Becauseofamultitudeofpharmacokinetic parametersdeter-
mining a given chemical's effective dose and the species-
variability ofparticularbiochemicalpathways whichdecideits
actualcarcinogenicity, Kis notexpected tohavethe samevalue
forallchemicals. Forthecomparisonofcarcinogenicpotencies
betweenmiceandrats, ithasbeenfoundthatKvaries afactorof
20over morethan200rodentcarcinogens(37,53). Ourtaskisto
find appropriate values for the factor KhR for the rodent to
humanconversion. (Here we usesubscriptRtoindicaterodents
ingeneral, reservingthelowercase rfor uselaterwhen werefer
specifically to rats.) Webegin with thehypothesis that a given
chemical or agent that is a carcinogen in one rodent species is
carcinogenic in another. We further propose that the carcin-
ogenic potency in humans is close to that in rodents (KhR = 1)
whenthepotencies are measured inunitsof(mg/kg-day)-', and
how close KhR is to 1 can be derived from experimental and
epidemiologicaldata. Ascientific study maydisprovethis pro-
position for agivenchemical orclassofchemicals, inwhich case
ourhypothesiswouldhavetobeabandoned ormodified. Possible
modificationmightbethatKhRis, on average, closer to 10, or to
0.1. The whole process ofrisk assessment should therefore be
iterative. As biological understanding improves upon the
assumptions, the assessment may be modified appropriately.
Some government agencies have made various assumptions
aboutthisfactorintheirriskassessments; these are summariz
in Table 1. But we reemphasize thatKhR is not a constant; it
variesfromchemicaltochemical,althoughgeneralizationsmade
on thebasis ofchemical class couldbe warranted.
lible 1. Comparison ofrelativeinterspecies potency factors
usedby somepolicymakersa
Method Rat Mouse Human Reference
mg/kg-day 1 1 1 CrouchandWilson(39);
(chemical weight/ Crouch(37) (Foodand
body weight) DrugAdministration)
Percentageofdiet 1 0.38 1.8 Andersonetal.(ll)
(chemical weight/
dietweight
(mg/kg-ay) x (W/r) 1 0.44 5.9 Andersonetal. (III)
(surfaceareacorrection) (Environmental Protec-
tionAgency)
(mg/kg-day) x ($/W) 1 0.29 14 Travis (38)
mg/kg-day x lifeime 1 1 35 NAS (162)
aThe numbers given are relative to potency in rats = 1. Wis the weight of
species x (mouse or human); Wis the weight ofthe rat. Weights used in the
calculations were rat: 0.35 kg, mouse: 0.03 kg, human: 70kg.
Deriving Potency in Humansfrom
Potency in Rodents
Thereareseveralpossibleproceduresforderivingcarcinogenic
potency inhumansfromthecarcinogenicpotencyinrodents. a)
Understandingthebiologicalprocessesrelevanttochemicalcar-
cinogenicity, theirkinetics, andhowthesedifferbetweenrodents
and humans. b) Comparing "natural," background tumori-
genesisinrodentsandhumans. c)Comparingcarcinogenicityof
chemicals inrodents andhumans inthosecases wherethere is
adequateepidemiologyinhumans. d)Comparingcarnnogenicity
ofchemicalsinratsandmice, therebyobtainingwhatisprobably
an upper limit on the accuracy of the comparison between
rodents andhumans.
UnderstandingBiologicalMechanismsof
Carcinogenesis
The fact that interspecies variation in biological processes
plays an enormous part in carcinogenesis can be seen by a
reductio-ad-absurdiumargumentdueto Peto(54). Supposethat
alltissuesofahumanandamousewereequallylikelytodevelop
neoplasmswhen, forexample, bombardeduniformlybyioniz-
ing radiation. The probability ofgetting a tumor in any given
timeperiodisthereforegreaterforahuman hanamouse(simply
becausethereis moretissue)bytheratioMh/Mm, whereMhand
Mm are the masses ofthe human and the mouse respectively.
Nowtheincidenceofcanceriswellknowntoincreasewithage
byapowerofthetime(55-57), theexactpowerdependingupon
thetypeofmalignancy. Letusassumethefourthpower. Thenthe
probability ofdeveloping a tumor during the mouse's lifetime
T. is less than that ofdeveloping one during the human's
lifetime Thby(Tm/lTh)4. Thereforeweexpectthatthelifetimein-
cidenceofradiation-inducedcancerinmicewillbelessthanthat
inhumansby afactorofapproximately
(Mm/Mh)(Tm/Th)4 z (30g/70kg)(2 years/70years)4 = 1/109.
Yetevidence suggeststhattheactual mouse/human ratio for
radiation-inducedcancerisclosertounity(58). Weallknowthe
answer to this.paradox in general terms: it is because the se-
quenceofbiochemicalandphysiologicaleventsleadingtocar-
cinogenesisproceedsmorerapidlyinmicethaninhumans. The
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rates ofcell division arefaster in smalleranimals. Thecardiac
outputofa mouseis 100% ofitstotalbloodvolumeperminute,
whereasthatofamanisonly5% ofhisbloodvolumeperminute
(59). These and otherfactors, both understood and unknown,
resultindifferentialprobabilitiesandlagtimesfortumorinduc-
tion, anddifferentdose responses.
Theproblemfacing us is tofindthebestestimatethatwecan
oftheactualpotency ratioforchemicalcarcinogenesisbetween
experimentalanimals andhumans. Clearly, whenestimating a
givenchemical'scarcinogenicpotencyinhumansfromitspoten-
cy inrodents,allavailableinformationondifferencesintherates
andmechanismsofitsabsorption, distribution totargetorgans,
biochemical transformation to active or inactive metabolites,
clearance, and mechanismsofcarcinogenicity shouldbetaken
intoconsideration(60). Attention todifferentialpharmacokinet-
icsmaybeofespecialimportance tothelow-doseextrapolation
(61). Unfortunatelyforthefieldofquantitativeriskassessment,
suchinformationislackingformostchemicalsproventobecar-
cinogenic in animal bioassays. But evengiven detailed know-
ledgeofpharmacokineticandotherrelevantbiologicalbehavior
in onespecies, thereis notyetanyformulaforcalculatingquan-
titatively a chemical's tumorigenicity from its actions at the
molecular, cellular, or organ level. On the otherhand, where
suchdata areavailablein twoanimalspeciesforachemicalthat
hasbeentestedforcarcinogenicityinboth, itshouldbepossible
tocalibrate somebiologicalparameters tocarcinogenicpoten-
cy. Ifthesesameparameters canbeestimatedinhumans, forex-
ample, bymeasuringurinemetabolitesinexposedpopulations
(62) or by analogy with related compounds (especially an-
ticancer drugs) for which such data exists, then the animal-
humanextrapolation wouldthereby be facilitated.
Thequestionofwhethertargetorgantoxicityisaprecursorto
tumorigenesis wasrecentlyadddressedbyHoelandco-workers.
Ninety-ninechemicals weretestedforcarcinogenicityandsite-
specifictoxicityinlong-termrodentbioassays;only7ofthe53
which werepositive forcarcinogenicity exhibitedtargetorgan
toxicity thatcouldhavebeencausal totheobservedneoplasms
(63). However, somelocalresponsesnormallyassociatedwith
toxicity, such ashyperplasiaandinflanunation, wereconsidered
bytheseauthorstobecorollariesofneoplasiaratherthantoxicity.
Bydefiningtheseresponses aspreneoplastic, itappearstousthat
they have ruled outapriori whatmightbe aninterestingeffect.
Itwouldhavebeen moreinformativetoask, instead: whichtoxic
effects areassociatedwithneoplasia?Thereforeitis notclearto
uswhethertheyhaveadequatelytestedtherelationshipbetween
toxicity andcarcinogenicity.
Greatstrideshavebeenmadeintheareaofbiologicallybased
modelingofthe ratesofprogressthroughthestagesofcarcino-
genesis. Models inwhichcarcinogenesisproceeds inaccordance
with tworate-limiting, heritable, cellulartransitions(from nor-
mal tointiated andfrominitiatedtotransformed), andinwhich
theclonalpopulationsizeandthemitoticrateoftheinitiatedcells
are included among the variables, have been successful in
explaning theincidenceofvarious human cancers(64,65) and
chemically inducedbladder cancerin rats(66). Furthermore,
experimentationbaseduponsuchmodelshaspermittedelucida-
tionofthemechanismofactionofatleastonenongenotoxic,low-
potencycarcinogen: it wasconcludedthatthetumor-promoting
attributesofsodiumsaccharin areduetoincreasesintheinitiated
cellpopulationandmitoticrate(butnottheprobabilityofinitia-
tion),andthattheseeffectsaresecondarytocytotoxicity(67,68).
Suchadvancesinunderstandingthecellularphenomenologyof
carcinogenesis should result in the development of sensible,
short-term, in vivoanimalteststhatmightpredictlow-dosecar-
cinogenicpotency inhumans with ahigherdegreeofaccuracy
and at substantially less costthan a lifetime bioassay. There is
also a need for studies designed to determine the low-dose
response to tumorpromoters in long-term animalbioassays in
whichtheanimalshavebeenpretreatedwithaninitiatingagent
(69). Suchstudiesmightthenprovideacalibrationscaleforpast
andfutureshort-termin vivoinitiation/promotionexperiments,
suchasthoseproposedbyPbtter(70,71)orbyKunzetal. (72).
Butforthetimebeing, itmustbekeptinmindthattheexisting
methodsformodelingdonotpredictthecarcinogenicpotencies
ofchemicals;rather,theyofferameansofpredictingthenumber
oftumorsproducedandtheirrateofappearancegivenafixedset
ofvariablessuchasthenumberofnormalandinitiatedcellsand
the rates ofmitosis, differentiation, and death. Many ofthese
variables areexpected todependupon theparticular chemical
under test, the dose at which it is administered, and the back-
groundofinitatedcellsintheorganunderstudy. Wedonotknow
of any published report in which carcinogenic potency was
derived from an experimental system designed around a
biologicallybasedmodel, andwhichisdirectlyapplicabletoin-
terspeciesextrapolation. Weanticipatethatfutureattempts will
entailcalculationofaninterspeciespotencyfactorforeachclass
ofchemicalcarcinogens, baseduponthephysiological param-
eters discussed above.
Our present inability to predict carcinogenic potency given
detailedpharmacokineticdataandinformationastogenotoxicity
onshort-termtestsreflectsagenerallackofunderstandingofthe
mechanismsofcarcinogenesis. Amidmuchenthusiasmoverthe
associationofmsoncogeneswithneoplasticcells, therehasbeen
a question as to whether mutation ofa ras proto-oncogene is
causativeforthedevelopmentofsomehumanmalignancies or
is a consequence ofthem (73). This problem may have been
solvedby recentanalysisofrasmutationsintheleukemic cells
ofrelapsedpatientswhohadundergonechemotherapy. Fourpa-
tients in whom mutations in ras genes were detected upon
presentation no longer exhibited ras mutations upon relapse
followingchemotherapy-inducedremission. Itnowappearsthat
thebonemarrowprecursorsoftheleukemicwhitecellsdidnot
containthe rasmutation, whichthereforemusthavearisenina
laterstageofthedisease(74). Othertheoriescontinuetobefor-
mulated and revised. The hypothesis that all carcinogens are
mutagens(21)hasbeenreplacedby onewhichsuggeststhatall
initiators are genotoxic (75,76) and that tumor promoters are
agentswhichdirectlyorindirectlyincreasethemitoticrateofthe
initiatedclonalcellpopulation(66,64). Ithasbeenproposedthat
the carcinogenicity ofnongenotoxins, including those that act
only as tumorpromoters orincompletecarcinogens, is secon-
darytoa)site-specificcellulartoxicity(4,77),perhapsmediated
byoxygen radicals(78)orb)hormonalorimmunologicaleffects,
including stimulationofcellproliferation.
Thephenomenonoftumorprogressionisstillnotwellunder-
stood,althoughitappearsthatthis, atleastforsomecancers,may
beastageaffectedbyenvironmentalcarcinogens. Asdiscussed
byHigginson, latentcarcinomaoftheprostate occurs withthe
samehigh(10%)incidencein75-year-oldblackandwhitemen
in the U.S. and in Japanese men, whereas active prostatic
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carcinomawhichisthendiagnosedismuchrarer,occurringinthe
ratio60:30:1 inthesesamepopulations(79). (For 1984-1986,the
average yearly age-adjusted death rate for prostate cancer was
0.0232% inU.S. malesand0.0051% inJapanesemales.) Differ-
encesintheincidenceoftheactiveformarethoughttoreflecten-
vironmental(perhapsdietary)influencesontherateoftumorpro-
gression. JapaneseimmigrantstotheU.S. haveamarkedlyhigher
death rate from cancer ofthe prostate than those remaining in
Japan (80).
HeritablechangesinDNAmayonlybeamongthefirst(andlast)
ofa sequence of events necessary to the creation ofa typical
cancerouscell. Thereisevenaquestionastowhethersingle-base
mutation, which is the lesion detected in the typical bacterial
mutagenesis assay, is on the pathway for creation of most
neoplasmsaffectinginternal organs. Ithasbeenpointedoutthat
persons with the inherited syndrome xeroderma pigmentosum
(XP), whosufferfromoneofseveralgenedefectsresultinginlack
ofanenzymeactivitynecessaryforexcisionrepairofmismatched
basepairs, donotappeartohaveanincreased incidenceofinter-
nalcancers (81). ThisinspiteofthefactthatXPpatientsaremore
than 1000timeslikeliertodevelop UV-inducedskincanceronex-
posedareasofthebodythannormalpersons. Conversely,persons
with Bloom's syndrome, an inherited disorder involving
chromosomal fragility (resulting infrequentrearrangements and
other aberrations), have an extraordinarily high age-adjusted
deathrateduetovarioustypesofcancer(81). Outof103Bloom's
syndromepatients diagnosed in a 30-yearperiod, 28 malignant
neoplasmsweredetectedatameanageof2O.7years(82). Cairns
hasconcludedthatsimplebasepairmutationsarenotlikelytobe
therate-limitingcomponentsinmosthumancarcinogenesis, and
thatmajorgenomicchangessuchasrearrangementsanddeletions
areprobablymoreimportant(81). Ithasalsobeennotedthatthe
presence ofmutagenic substances in the urine ofsmokers (62)
"results in only a moderate excess of urinary and pancreatic
cancersandinnolargeexcessofleukemias, lymphomas, orsolid
cancers atother sitesdistantfrom therespiratory tract" (83).
Accordingly, sincewe areas yetwithoutamethod forderiving
carcinogenic potencies from biological first principles, it is
useful to lookateachoftheindirectprocedures listedabove. This
raises interesting andimportantquestions inscientific inference,
and as in all such problems, it is vital to get the assumptions
straight. The first assumption is that a substance which is a
carcinogeninonepersonis alsoapotentialcarcinogen inevery
other person. We make the further assumption that the car-
cinogenic potency is about the same in each case, although we
knowthatthisisanoversimplification(seebelow). Sincecancer
ismulticausal, theeffectofagivencarcinogenmaybeaffectedby
thepreviousorsubsequentactionsofotheragents. Ifoneisaware
of what the other predisposing factors or agents are, then the
assumption is modified to apply only to persons with similar
histories of exposure. In the most obvious example, cigarette
smokers are found to have higher incidences ofmany types of
malignancies, andtobecomeprogressivelymoresusceptiblewith
increasingalcoholconsumption(84), whichsuggeststhatsmok-
ingconfers enhancedsensitivity tochemicalcarcinogenesis.
Intraspecies Heterogeneity ofResponses
Although human genetic heterogeneity is a real and largely
uncontrollablevariableinthescalingofcarcinogenic potencies
fromlaboratoryanimalstoman, thereisevidencetosuggestthat
thedifferencesinsusceptibility arenotlarge, exceptforasmall
percentageofpeople who are highly vulnerable. Knudsonhas
suggested that there might exist four groups ofpersons with
qualitatively different susceptibilities to cancer (85). The first
group isimpervious toenvironmental effects; the secondgroup
has what we consider to be a "normal" susceptibility to car-
cinogenesisviachemicalagents, viruses, andotherenvironmen-
talfactors; thethirdgroup(whichincludespersonswithXPand
Bloom's syndrome)hasagenetic susceptibility toenvironmen-
talcarcinogens; and the fourth grouphas aninherited gene (or
developmentally sustained somatic genetic defect) that is
equivalent to the first irreversible step along the path toward a
particular cancer (85). Knudson points out that there are no
distinctlinesdividingthefirstthreegroups, andthatwhereas it
is nowconsidered likelythatmosthumancancerbefalls group
two, infactgrouptwomightbeasubsetofgroupthree, meaning
thatvirtually all susceptibility toenvironmental carcinogenesis
mighthaveageneticbasis (85). Wenotethatunless oneunder-
standsallenvironmental variablesandcontrols forthem, itisnot
usually possible to differentiate between apopulation distribu-
tionofgenetic susceptibilitiesandasimilardistributionofother
factors such as exposure to dietary carcinogens.
That atleasttwo-thirdsofall cancers (excluding skin) can be
attributed to environmental rather than genetic influences was
demonstrated by thepioneering work ofHigginson andOettle,
whocomparedthecancerincidences oftheSouthAfricanBantu
with U.S. blacks (86). More recently, ithas beenestimated that
at least 75 to 80% of cancers are the result ofenvironmental
influences, which include smoking, alcoholconsumption, hor-
monal factors controlled by behavior (such as age at first preg-
nancy), diet, viruses, ionizing radiation, and chemical car-
cinogens from sundry sources (79,84,87). The factthat, except
forrarecasesofidentifiableindividuals athigh risk, geograph-
ical clusters ofcancerattributable toenvironmental causes seem
tobedistributed over theexposed population, rather thanbeing
concentrated in families or within ethnic groups, suggests that
there isadefinableupperlimitontherangeofsusceptibilities in
the population at large.
A review ofhumanphenotypic variability with respectto the
metabolism ofseveral classes ofcarcinogens and pro-carcino-
gens showedthat inmostcases the spread in rates ofenzymatic
deactivation and activation was within an order ofmagnitude.
Foronecaseinwhich thedistribution was moreextreme (three
to four orders ofmagnitude for debrisoquine oxidation), there
was also a marked variation among seven rat strains (88). The
finding ofhuge phenotypic variation in some biochemical ac-
tivities relevant to carcinogenesis is not, however, an indicator
ofprevalence. In theexample noted, 75 to 80% ofhumans were
found to fallwitiina 10-foldrangeofdebrisoquine oxidation ac-
tivity. Itisalsonotunreasonable toimaginethat, giventheoverall
biochemical heterogeneity ofour species, anindividualmightbe
more predisposed than average to develop a particular type of
cancer and less predisposed todevelop another. We expect that
the net variability in susceptibilities (within the "normal"
population) ineachcase tobeless thantheexpected errorinthe
scaling ofcarcinogenic potencies fromrodents tohumans, which
is predicted to be accurate only within an order ofmagnitude
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on average, andissometimes accurateonly towithin twoorders
ofmagnitude(39,89). Therefore, inmostofwhatfollows, excep-
tionsandcaveats to ourstatedassumptionswillbeignored. The
questionofwhichanimalmodelbestsimulatesthetypicalhuman
response maybeconsideredwhensuchinformationisavailable.
Pharmacokineticstudiesofsomechemicals mayalsosuggestthat
the animal data extrapolates better to a fraction ofthe human
population which is more (or less) sensitive than average.
Comparison ofSpontaneous CancerIncidence
(Background Tumors)
The use of animal models for human carcinogenesis was
originallybased, inpart, onthegeneralobservationthatanimals
inthewildhaveroughly the sameoverall ratesofmalignancy as
humans. Use ofinbred rodent strains in carcinogen bioassays
later became commonplace, and strains have been developed
which, intentionally or not, are moresusceptiblethanothers to
spontaneousandinducedneoplasms atparticularsites; e.g., liver
tumors in male B6C3F1 mice. In an attempt to maximize the
likelihoodofdetecting a carcinogenic response, ultra-susceptible
strains have been used frequently in long-term bioassays. The
deliberate useofstrains having high, site-specific, spontaneous
tumor ratesinevitably forces usto reexamine onemajorrationale
forthe useofanimals asmodels. A convictionoften expressed
is thatchemical carcinogenesis at somehighly sensitive site in
an inbred rodent strain does not necessarily predict carcino-
genicity at anysiteinhumans. Theviewheldby oneofus(G.G.)
is that carcinogenic effects in animals can be extrapolated to
humans morelogically whentheanimalsundertest arenotsub-
ject tounusually highbackground ratesofcancer, whetherthese
increased rates aregenetically determined or areartifactsofthe
experimental design. Analternativeview (heldbyR.W.) isthat
while it is likely that chemical carcinogenesis in animals with
highbackground tumor rates atparticular sitesdoespredict car-
cinogenicity inotherspecies, theinterspecies conversion factor
is probably lower forthese sites.
Determination of background cancer rates in humans is
somewhat of a subjective process. Without a detailed un-
derstanding ofall the factors which produce tumors, the best
that one can usually do is to assume that the lowest rate observ-
ed for a given site (in all populations) is the background rate.
As discussed above, it has been estimated that at least 75 to
80% of malignancies occurring in people living in the de-
veloped nations are attributable to environmental factors, in-
cluding diet. The percentage ofU.S. deaths due to cancer was
22% in 1985, according to the Bureau ofVital Statistics. Based
on this figure, the background (nonenvironmental) cancer rate
in humans would be less than approximately 0.25 of22%, or
5.5%. the results ofseveral human autopsy studies suggest that
the overall incidence of cancer is higher than 22%; approx-
imately one-third ofautopsies revealed cancer, and a surpris-
ingly high percentage ofthe neoplasms found had been either
misdiagnosed or undetected before death (90). Based on this
autopsy estimate, the background cancer rate would then be
0.25 of33%, or 8.3%. However, since human autopsies are not
expected to be as thorough as histopathological examinations
performed at the end of2-year rodent bioassays, this estimate
is probably still too low.
Table 2 lists control tumor rates (forall sites combined) from
theunpublished NTPhistorical controldatabase for strains com-
monlyusedincarcinogenicity bioassays; these rates range from
9% to more than 50%. It has been pointed out that the usual
laboratoryregimeresultsinoverfed,overweightanimalswithen-
docrine disturbances and other abnormalities, and that these
animals are therefore unsuitable for carcinogenicity testing of
chemicals(91,92). Itispossibletoaffectthebackgroundtumor
rate for laboratory rodents by altering this regime; an easy
methodistoreducecaloric intaketo75% ofwhatis consumed
during adlibitum feeding. In one such study ofoutbred Swiss
mice, theincidenceoftotal malignanttumors in otherwiseun-
treatedanimalswasloweredfrom 11 to4.4% inmalesandfrom
14to4.4% infemales (91,93). (ResultsoftheConybeare study
areincludedinTable2, alongwithsomehumancancerrates, for
comparisonwiththeNTPcontrolgrouprates.)Inasimilarstudy
involving inbred rats, the incidence of malignant mammary
tumors was reduced from 25 to 3.8% in females; pituitary
adenomasdroppedfrom24to3.8% inmalesandfrom48to 10%
infemales(94). Theseobservationssuggestthattheratesoftrue
spontaneousneoplasmsinrodentsaresimilar(withinafactorof
2)tothoseinmanwhendietisgivenproperconsiderationasan
environmental variable.
It seems reasonable tohypothesizethatthepotency ofacar-
cinogenwhenexpressedasafractionormultipleofbackground
effectswillbesimilarinrodentsandhumans. Wehaveneverseen
explicitly stated the argument that comparison ofbackground
tumor rates implies that KhR 1, but it has been frequently
implied and used. One of the major inadequacies of this
hypothesisliesinitsimplicitassumptionthatcarcinogenesis via
environmental agents ismechanistically similartospontaneous
carcinogenesis. Thissubjectisnotyetclosetoresolution. Aless
Table2. Comparison ofoverall tumorincidences inlaboratory
animalsandhumans.
No. of % with tumors
animals Malignant Benign Total
Control animals for2-year NTPbioassaysa
B6C3F1 Mice
Males 1692 42 35 64
Females 1689 45 33 64
F344 Rats
Males 1596 55 95 98
Females 1643 38 76 88
Osborne-Mendel Rats
Males 50 26 68 78
Females 50 12 80 88
Sprague-Dawley Rats
Males 56 8.9 36 39
Females 56 30 68 79
Effectofdiet onoutbred Swiss miceb
Adlibitumfeeding
Males 160 11 44
Females 160 14 31
75% ofadlibitum feeding
Males 160 4.4 23
Females 160 4.4 11
U.S. Cancerdeath rates
BureauofVital Statistics, 1985
Males 22.5
Females 21.7
Estimated spontaneous ratesc
Malesand females 5.5
Estimated upper limiton
spontaneous ratesd
Malesandfemales 12
aNTPhistoricalcoiitrol data.
bConybeare (93),tabulated byRoe(91).
CDoll and Peto(84).
dFrom observations on Mormons by Lyonetal. (163).
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formidable problem is the discrepancy between animal and
human data due to the reporting only of diagnosed human
malignancies and not all tumors. Neoplasms that were un-
diagnosedpriortodeathand/ordidnotleadtodeatharenotnor-
mally counted.
For the sake ofconformity with available data on the occur-
renceofhumanneoplasms, onecould removefromconsidera-
tionlatentmalignancies inrodentsthatdonotleadtodeathand
aredetectedonlyduring routinebiopsy, suchastesticulartumors
in aged male rats. Alternatively, one may include latent
malignancies tomaximize statistical significanceandthencom-
pensatefortheelevationoftheobservedpotency soastoderive
aninterspeciesconversionfactorapplicabletoactiveneoplasms.
Interspecies Differences in the Tumor Siteof
Highest Sensitivity
Ifthebackground rates ofsite-specific neoplasms aresimilar
inanimals andhumans and ifmalignancies inducedby agiven
chemical agentoccur atthe same sites inanimals andhumans,
thentheinterspeciesextrapolationwouldbestraightforward. Un-
fortunately, inrealitythingsarenotsosimple. Carcinogensoften
induce neoplastic responses atdifferent sitesindifferentspecies.
Another difficulty in making theanimal/human comparison is
thatmosthumandataontheeffectsofexposuretochemical car-
cinogensareformalignancies atonlythemostsensitivesite. This
does notimply thatother sites areunaffected. Forany study of
carcinogenesis in humans or animals, choosing the site ofthe
dominant neoplastic responsewillconferhigherstatistical sen-
sitivity on the result than would choosing any other site. A
bioassay ismore sensitive still ifanincreaseinanunusualtumor
is found, i.e., onethatrarelyoccursspontaneously. Thereisalso
some evidenceto suggestthatthe interspecies (mouse/rat) cor-
relationis strongerforchemicals whichproduceraretumors in
rats than for those which produce only common tumors (95).
Initially, scientists oftenmadetheassumptionthatachemical
whichcausescanceratagivensiteinonespecies islikely, inthe
absence of information to the contrary, to cause cancer at the
samesiteinotherspecies. Moreover, itseemedtomakesenseto
look for cancer in those organs which manifested lesions in
response to toxic insult. For example, when aflatoxin B1 was
shown to cause hepatic necrosis in poultry, pigs, and calves, it
was immediately tested for hepatocarcinogenic activity in rats
[reviewed byBusby andWogan(96)]. Itisnow wellknownthat
aflatoxin B1 is a highly potent rodent carcinogen. Although a
clear association between hepatocellular cancer and aflatoxin
intake was found in the earliest studies ofhuman populations
exposed to high levels ofaflatoxin Bl, interpretation was com-
plicated due to frequent simultaneous infection with hepatitis B
virus. But several studiespublished since 1984have specifical-
ly addressed this question of confounding; it has now been
establishedthataflatoxinB1 ingestionisahighriskfactorforliver
cancer, above and beyond hepatitis B infection (97,98). Vinyl
choride isanotherexampleofachemicalwhichwasknowntobe
toxic to the human liver before being studied for possible he-
patocarcinogenicity. In three rodent species a rare liver tumor
(angiosarcoma) has beenproduced byvinyl chlorideinhalation
(99,100); angiosarcoma has also been found in humans among
vinyl chloride workers (IOI).
Weareinterestedintheoverallincrease incancerinhumans
duetoexposure to agivenchemical carcinogen, yetoftenonly
theincidenceatthemostsensitivesiteisrecorded. Isitpossible
topredicttheexcesscancerincidenceatallsitesgiventheexcess
incidenceatthe most sensitive site? Ifso, thenanapproximate
correctionfactormaybeobtainedasfollows. Itiswellknownthat
theprincipal siteofcancerduetosmokingisthelung. IntheU.S.
in 1985, therewere 122,700lungcancerdeaths. Ofthese, approx-
imately 112,240 were due to cigarette smoking (102). But a
numberofothercancersarealsolinkedtocigarettesmoking. The
number of U.S. deaths in 1985 due to cancer other than lung
cancerwas338,870; oftheseanestimated30%, or 101,660, were
also attributable to smoking. Thus, for those cancer deaths
causedby smoking, theratiototal/lung is (101,660 + 112,240)/
112,240 = 1.9. Forvinylchloride, theexcessofmalignancies at
nonhepatic sites is less than the excess ofall liver tumors in-
cludingangiosarcomas(103,104), andinarecentmortality study
ofvinyl chloridemanufacturing workers, angiosarcomas were
foundto makeuphalfofthetotal livertumors (105).
CrouchandWilsonlookedattheratioofthesumofpotencies
atallsitestothesumofpotenciesatthemostsensitivesiteforall
chemicalswhichhadbeentestedbytheNCI/NTPasof1978and
whichhadbeenjudged tobepositive forcarcinogenicity; they
foundthattheratioofthesumswasapproximately2inmostcases
(unpublisheddata). Forevaluatinganinterspeciesconversionfac-
tor,theysuggestedusingonlythedataforthemostsensitivesitein
bothspecies;statisticalvalidityisimproved,andthefactorsoftwo
tendtocancel(39). Afactoroftwoissmall,inanycase,compared
tootheruncertainties inherentintheinterspeciescorrelation.
Inpractice,themouse/ratandrodent/humaninterspeciescom-
parisonsdocorrelatemorecloselywhenthetumorsiteisallowed
tovarytoaccommodatethemostsensitivesite. Inasurveyof58
chemicals, Tomatisetal. foundacorrelationbetweeninduction
oflivertumorsinmouseandinductionoftumorsatanysiteinrat
andhamster(106). Thisqualitativecorrelation wasstrongerfor
chemicalsthatalsoinducetumors inmiceofboth sexesatsites
inaddition to liver. Itwas laternotedthat ifroutes ofexposure
aresimilarforanimalsandhumans, thenthetargetsitesaremore
likelytocoincide, althoughmoresitesinanimalsareusuallyaf-
fected(107). Itwasthereforeproposedbytheseauthorsthatin-
ductionofany animal tumor shouldbeconsidered asevidence
forpossiblehumancarcinogenicity, even iftumors atthatpar-
ticularsitehavenotbeenshowntooccurinhumans. Adramatic
argumentinsupportofthisapproachcanbefoundbyexamining
the history of the known carcinogenicity of benzene. This
chemicalhaslongbeenassociatedwithleukemiainhumans, but
wasnotobservedtoproduceneoplasmsinratsormice. Nowre-
centstudieshaveshownstatistically significanttumorincidences
atnumeroussitesinrodentsexposedby ingestionorinhalation
(108)andgavage(109). Anexaminationofhumandataforeffects
atmultiple sites revealed apossibleassociation with tumors at
onlyafewofthesitesaffectedinrodents: multiplemyelomaand
lymphatic andhematopoietic neoplasia (110).
For some time, the above argument has been the basis of
regulatoryphilosophy, e.g., asdescribedbyAndersonetal.(IMl).
Itisnowcommonpracticetoevaluateachemical'scarcinogenic
potencyinanimalsandhumansintermsofthemostsensitivesite,
withthecaveatthatsiteswithanextraordinarilyhighbackground
incidence, suchastheliverinthemalesofsomemicestrainsor
thetesticlesofF344 rats, are sometimes disregarded.
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Should WeInclude BenignTumors?
Inthe regulatorycommunitythereisconsiderablediscussion
about whether to includebenign tumors along with malignant
tumorswhendetermining potency inrodents forthepurposeof
predicting potency inhumans. The presenceofbenign tumors is
generally accepted as ahighly probable indicationofeventual
malignancy (97,112,113). Ifthisisthe case, thentheinductionof
benigntumorsby achemical shouldbeconsidered asevidence
ofthat chemical's carcinogenicity. Recently, the relevance of
benignneoplasms wasevaluatedfor 143chemicalstestedinNTP
bioassays. Only five chemicals produced solely benign
neoplasms, andthoseobserved are knownto representtransitory
or progressive stages in thedevelopment ofmalignancy (114).
Qualitativelythen, achemical'sability toinducebenigntumors
is indicative ofits carcinogenic potential. However, in a quan-
titative statement of rodent carcinogenicity, benign tumors
shouldonlybeincludedifthey arealsoincludedinthedefinition
ofthe rodent-to-human interspecies conversion factor for car-
cinogenicpotency. IfwegenerallyevaluateKby someprocedure
withoutincludingbenigntumors, wemightnevertheless wishto
includebenign tumorsfor aspecific chemical inordertoobtain
apotency thatis statistically significant. Wecouldthen usethe
value ofKderived without benign tumors if we multiply the
potency forinductionoftotal tumors(benignand malignant) by
the averageratioofmalignanttototaltumorsfoundinchemical
bioassays.
Human/Rodent Chemical
Carcinogenicities
Qualitative Comparison (Human/Rodent)
Inallthere are now50chemicals, groupsofchemicals, orin-
dustrial processes forwhich anIARCWorkingGrouphas con-
cludedthatthereissufficientevidenceofhumancarcinogenicity
(97). For most, the data on human exposures is inadequate to
calculate aquantitativerisk, andhencethereis noopportunity
todo ahuman/animal comparison oftheircarcinogenic poten-
cies. But we canfirstaskthesimplerquestion: dothesehuman
carcinogensalways cause cancerintestanimals?Wibournetal.
(IIS) evaluated the animal carcinogenicity of30chemicals (or
groupsofchemicals) forwhichsufficientevidenceofhuman car-
cinogenicity wasreported inIARCMonographs volumes 1-41.
These are listed in Table 3. (The authors excluded certain in-
dustrial exposureswhich were amongthe50LARChuman car-
cinogens.) Ofthese30humancarcinogens, there wassufficient
evidenceofanimalcarcinogenicity for 18 andlimitedevidence
for7;datafor3 wereinadequate, andfor2there were nodataat
all. The latter 5 agents are arsenic, certain combined chemo-
therapies (including MOPP [mechlorethamine, vincristine,
prednisone, andprocarbazine]), conjugatedestrogens, smoke-
lesstobaccoproducts, andtreosulphan. Notethattheseauthors
found that "new data wouldprovide limited evidence" for the
animal carcinogenicity of arsenic, referring to the work of
Ishinishi etal. (116) and Pershagen etal. (117), which werethe
first adequate studies in which arsenic was administered via a
respiratory route. It wasalsopointedoutthatthereis sufficient
evidence of animal carcinogenicity for some components of
MOPP, namely, nitrogenmustardandprocarbazine. Ofthere-
maining 3agents, theconclusionofWilbournetal. wasthatthey
"hadnotbeenadequatelytestedinexperimentalanimalsandno
statementcanbemaderegrdingtheircarcinogenicity inanimal
models" (115). In the most recent IARC assessment, limited
evidence was also found for the carcinogenicity ofconjugated
estrogens in animals, based on studies published in 1983 and
1984(97). Forarsenic,thisIARCreportcitedanumberofstudies
publishedsince 1981 insupportoftheconclusionthatthere now
exists limited evidence ofits carcinogenicity in experimental
animals.
Webelievethatitmakesfarmoresensetodiscussachemical's
carcinogenicpotencythantheprobabilityorpossibilityofitscar-
cinogenicity. Incaseswheretheobservedincreaseinneoplasms
isnotstatisticallysignificant, anupperlimittothepotency can
bederived. Thefollowingexampleillustratestheimportanceof
thisapproach. Tenyearsago,evidenceforthecarcinogenicityof
benzenewasconsideredinadequateorinconclusive. Theobser-
vationwasmadethatsincebenzene-inducedleukemiainhumans
occurredatonlyaverylowincidence, studiesinanimalscould
notbeexpectedtoproduceastatistically significantincreasein
leukemiaorany othercancerunless largenumbers ofanimals
wereexposed(118). Thisanalysistacitlyassumedthatthepoten-
cyinanimalswasofthesameorderasthatinhumans. Upuntil
that time, no adequate study (lifetime exposure, sufficient
numbers, high enough doses) ofbenzene's carcinogenicity in
animalshadbeenundertaken. Ithasbeendemonstratedsincethat
benzenecausescancerinrodentsatratessimilartowhatwasex-
pected from the data in humans (108,109,119,120). Recent ex-
perimentalevidencepromptedWilboum etal., intheiranalysis
oftheresponseofanimlstohuman carcinogens, tofootnotethe
"limited" evidenceforbenzene'scarcinogenicityinanimalswith
the statement, "new data would provide sufficient evidence"
(115). The absence in 1978 of benzene-induced neoplasia in
rodents did notdisprove theproposition that the carcinogenic
potencyofbenzeneisapproximatelythesameinrodentsasitis
inhumans, althoughitwassometimesmistakenlythoughttodo
so.
Quantitative Comparison (Human/Rodent)
In 1977, MatthewMeselsonandSirRichardDoll suggestedto
oneofus(R.W)theimportanceofquantitativecomparisonofthe
carcinogenic potencies in humans and laboratory animals for
chemicals forwhichhumandatawereavailable. Theresultsof
aninitialstudywereincludedinapaperbyCrouchandWilson
(39). Thereareseveralgreatpracticaldifficultiesinundertaking
thiscomparison. Thefirstisthattherearealimitednumberof
chemicals that are known to cause cancer in humans. In 1978,
there were only approximately 25 substances on this list,
including somewhichareclassesofchemicalsratherthanuni-
quecompounds. Theseconddifficultyisthatthehumandata, for
themostpart, areforuncontrolled, unmeasured, short-termex-
posures. Consequently,epidemiologicalstudiestypicallyrelate
cancertoexposureonlyqualitatively. Thetiirddifficultyisthat
once achemical has beenbranded a "humancarcinogen," at-
temptsaremadetobanit, andinterestinassessingitseffectsin
animals declines. Thus, for many known human carcinogens
adequate testing inanimalshas notbeendone.
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Table 3. Chemicals for which IARC found sufficient evidence of
humancarcinogenicity (1U5).
Chemical Evidence in animals
4-Aminobiphenyl Sufficient
Analgesic mixtures containing phenacetin Limited
Arsenic and certain arsenic compounds LiMiteda
Asbestos Sufficient
Azathioprine Limited
Benzene Sufficient
Benzidine Sufficient
Betel quid containing tobacco (chewing) Limited
N-N-bis(2-chloroethyl)-2-naphthylamine
(Chlornaphazine) Limited
bis(Chloromethyl)ether and technical chloromethyl
methyl ether Sufficient
1,4-Butanediol dimethanesulphonate (Myleran) Limited
Certain combined chemotherapy regimes for
lymphomas including MOPP"C No data
Chlorambucil Sufficient
Chromium and certain chromiumcompounds Sufficient
Coal tars Sufficient
Coal-tarpitches Sufficient
Conjugated estrogens Limited'
Cyclophosphamide Sufficient
Diethylstilbestrol Sufficient
Melphalan Sufficient
Methoxsalen with UV A (PUVA) Sufficient
Mineral oils (containing various additives and
impurities Sufficient
Mustard gas Limited
2-Naphthylamine Sufficient
Shale oils Sufficient
Smokeless tobacco products Inadequate
soots Sufficient
Tobacco Smoke Sufficient
Treosulphan No data
Vinyl Chloride Sufficient
aListed as "inadequate" in IARCMonographs seriesprior to 1987; see text for
details.
bListe as "limited" in IARCMonographs series prior to 1987; see text for
details.
cMOPP, mechlorethamine, vincristine, prednisone, and procarbazine.
We show inFigures IA and lB a comparison ofcarcinogenic
potency in humans to that in rats and mice, respectively, taken
from Crouch and Wilson(39). In most cases theseauthors had
to estimate human exposures by reanalyzing the data from the
original epidemiological literature. Consequently, the results
contain considerable uncertainy. The error bars delimit one
standard deviation. Where a bar has an arrow at the end, one
standarddeviation does notdefine alowerlimit; the errorinsuch
cases encompasses zero potency. The lines log (nlh) = log ((3,)
and log (nh) = log (fl.m) (i.e., Khr = Khm = 1) do not pass
through the errorbars onallthepoints. Nonetheless, theresults
areinroughagreementwiththepropositionthattheinterspecies
factor for rat to human(Kh.) and for mouse to human(KJ,, are
each about equal to 1, with most deviations falling within an
orderofmagnitude. Thisrangeissmallcomparedwiththerange
ofcarcinogenicpotenciesinrodents' whichvary overfiveorders
ofmagnitude. We note that the U.S. Environmental Protection
Agency (EPA) uses Khr = 5.9 andKh., = 13 in its risk assess-
mentprocedures(Table 1);byinspectionitcanbe seenthatthese
EPAvalues fortheinterspeciesconversionfactors aremorelikely
tooverestimate the risk. Althoughthesimplestproposition(that
Khr =Kh., = 1) isalmostcertainly notprecisely true, thepropo-
sition thatthe valuesofKandKh., arelognormally distributed
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about I is consistent with the data. Letting x representInl(Khr)
andln(Kh,,), theprobability offinding a valuex isgiven by
P(x)dx L exp (j)dx (2)
where the standard deviation a is to be determined.
Allenetal. performned amuchmoreextensivesurveyofhuman
carcinogenic potencies and made comparisons with rodent
potencies (89). As noted above, probably the most difficult
aspectofsuch astudy istheevaluationofhumanexposures. The
bestestimates ofthehumanTD25 values (with theirassociated
uncertainties) forthe20chemicals forwhich sufficientdata were
found is reproduced from Allen et al. (89) in Figure 2. Unfor-
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tunately, the detailed calculations upon which these estimates
werebasedareunpublished, sothatweareunabletojudgetheir
reliability. InFigure3 weshowtheirbasecaseplotofhumanver-
sus rodentTD25estimates. Wenoteherethattheyhavenotderiv-
edabestfitlineintheordinaryway. Theirstatisticalsignificance
statement is for how well the order ofthe potencies in rodents
correlates withtheorderofthepotencies inhumans. However,
byinspectionofFigure3 wededucethatthenumericalvaluesof
thepotenciesalsocorrelatereasonably well. Thesolidlinecor-
responds to Khr = Kh = 1; the dotted line, Khr = (Wht/Wr)'3=
5.9; the dashed line, Khm = (Wh/Wm)A = 13. It can be readily
seenthatKh,r 1andKhm= 1 aremorelikelypropositions than
Khr = 5.9 orKhm = 13. The relationship forP(x) in Eq. [2] fits
the data reasonably well with a = ln(5).
While making this statement, we emphasize that neither
Crouch and Wilson (39) nor Allen etal. (89) have proven that
KhR = 1. Theseauthorsmerelytestedapropositionandfound it
consistentwiththeavailabledata. Thisworkandrelatedworkon
the correlation between rat and mouse carcinogenic potencies
havebeencriticizedby FreedmanandZeisel, whohighlightthe
limitationsoftheavailabledataandinsistthatthepropositionthat
Kisdistributedaroundthevalueof1 isnotproven(121). Butin
fact, thepropositionhasnotbeendisprovenforanychemicalfor
whichadequatedataareavailableforbothhumanandrodentex-
posures. However, formostchemicalstheabovepropositionre-
mains untested. There may be chemicals for which the rodent
bioassay is a poor predictor of human carcinogenicity, with
potencies inhumans (ifthey weremeasured) suchthatKhR> >
1orKhR< <1. Weknowofnosuchchemicals, butthisdoesnot
meanthattheydo notexist.
Negative andInadequate Epidemiology
Whenweattempttocompareanimal andhumancarcinogenic
potencies, andinparticular, whenwetrytounderstandthecauses
of any discrepancies, we are impressed by the importance of
"negative epidemiology," i.e., studies where no statistically
significant effect was observed. The absence of a significant
effectdoesnot, ofcourse,provethatthechemicaldoesnotcause
cancer; rather, anyincreasedincidenceistoosmalltobedeter-
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mined unambiguously underthegiven exposure conditions. It
becomes useful to express the result as an upper limit to the
numberofcancersthatcouldhavebeencaused, andthen, ifthe
exposure level is known, to derive an upper limit to the car-
cinogenicpotency, andthereforeanupperlimittoKh, thelower
limitbeingzero. CrouchandWilsonintroducedthisconceptin
theircomparisons (39), anditwasalsousedbyAllenetal. (89).
Webelievethattherearemanymorechemicalstowhichitmight
beapplied. Forexample,contactwithchlordaneandheptachlor
did not increase the age-corrected lung cancer mortality in a
groupoftermitecontrolworkers, whoweremorelikelytoincur
higherexposuretotheseagentsthanwereanyothersegmentof
the population (122). Although this study did not correct for
smoking, an estimated upper limit on potency might still be
extracted.
We shall illustrate next how a probable limit on human car-
cinogenic potency can be derived from inadequate epidemio-
logical results. EnterlineandVirenhavereviewedtheevidence
for the association between kidney cancer and exposure to
gasoline fumes (123). Theyconcludedthatthebulkofevidence
fromcohortstudiesofpetroleum-refining ordistributionperson-
nel indicates a small excess of kidney cancers among older
workers exposed for long periods. Let us do a back-of-the-
envelopecalculationoftheupperlimittothepotencyofgasoline
fumesforinductionofrenalcancer, basedondatacitedbythese
authors. Exposurelevelsweredrawnfromastudyoftheambient
concentrationofhydrocarbonsatgasolinemarketingterminals;
the mean value oftheconcentration asdeterminedby personal
samplers (worn 27 hr) was found to be 5.4 ppm (124). The
highest renal cancer death rate reported for this industry was
0.15% forworkerswhohadbeenexposedfor20yearsorlonger;
thisexcesswasstatisticallysignificant(125). Theexpectedmor-
tality ratefromrenal cancerforthewholeU.S. population was
0.071%. Assuminganaveragemolecularweightof80daltonsfor
thevolatileconstituents, thenfora70kgmanworking 8hrwith
inhalation volume 20.8 L/min, the daily dose would be 2.8
mg/kg. Making the conservative assumption of a linear dose
response between 0 and 2.8 mg/kg-day, then the potency (3 =
(0.0015-0.00071)/(2.8 mg/kg-day) = 2.8 x 10-4(mg/kg-day)'.
(Forsimplicity weneglectcorrecting forlengthofworkinglife,
which wouldresult in alowerpredictedpotency.)
For calculation ofa corresponding carcinogenic potency in
rodents, weturn toalifetimestudy inwhichratsandmicewere
exposedtovolatilizedgasolinefor6hr/day(126). Adose-related
increase in renal cancer was found in male rats; interpretation
wassimplifiedbythefactthatthestrainofratsused, F344, has
a very low incidence of spontaneous kidney tumors. In dose
groupsof100animalseach, atdoselevelsof0,67,292,and2056
ppmtherewere,respectively, 0, 1,5, and7malignantneoplasms.
Because the gasoline was vaporized to completion by heating,
this study is notaperfectmodel forthehuman exposures. Ad-
justingthemolecularweightestimationto 128daltons toreflect
themostlyCgcompositionofcommercialgasoline, andassum-
ingaweightof0.5kgandaninhalationvolumeof0.10L/min, the
dailydosewas 120mg/kg. Sincetheresponseisessentiallylinear
in the rangeof0 to 292 ppm, we calculate the potency as (3
(0.05 - 0.0)/(120mg/kg-day) = 4.2 x 10-4(mg/kg-day)-'. (We
assumeherethattherewasoneneoplasmperrat. Ifthiswasnot
the case, then the incidence rate would be lower, as would the
potencyestimate.)InFigureL4, wehaveaddedthedatapointjust
calculatedtoafigurepublishedoriginallybyCrouchandWilson
(39).Withverylittleeffortwehavebeenabletoincreasethebody
20f7GOODMANAND WILSON
ofquantitative knowledge pertaining both to the carcinogenic
potencyofgasolineinhumansandtotheinterspeciescorrelation
factor.
There is anobvious tendency to concentrate onthosechem-
icals where adefiniteeffect inhumans has beenfound, and in-
deed uponthesethecorrelationprincipallydepends. However,
if a chemical is found tobe carcinogenic in animals and is not
foundtobecarcinogenic in man, itisofobvious interest todis-
cover the cause of this negative outcome. Is it because the
chemical is anexception tothecorrelation; people werenot ex-
posedatsufficientlyhighlevels orforsufficientlylongdurations
orbecause the available epidemiological data areinadequate?
Chemicals Not Known toBeCarcinogenic
toHumans
Ennever et al. discuss 29 chemicals for which at least one
epidemiological study had found no evidence of human car-
cinogenicity. They lookedatthequantitative (+/-)evidence for
rodentcarcinogenicity for20ofthesechemicals. Theyreported
thatonly one, methotrexate, wasnegativeinrodents, andthatthe
remaining 19 werepositive. Theyconcluded thatthespecificity
ofrodentbioassays forpredictinghuman noncarcinogensis very
low (127).
Whereas Ennever etal. looked forqualitative agreementbe-
tweenthe rodentcarcinogenicity bioassay andhumandata, we
wereable toask moremeaningful, quantitative questions about
the agreement by examining the actual TD50 values (128).
StartingwiththerodentTD50 atthemostsensitivesitefromthe
Carcinogenic Putency Database (CPDB) (129-131), wederived
apredictedhumanincidenceforthedegreeofexposureanddura-
tion of follow-up corresponding to the most comprehensive
epidemiological studyavailableandthencomparedthepredicted
incidencewiththeobservedincidence. Ifachemicalproduced
nostatistically significantincreasein canceratanysiteinthe ex-
posedpopulation, consistency withrodentresults is inferred if
theminimumrodentTD50issufficientlyhighthat noattributable
cases wouldhave beenexpectedunderthe actual conditions of
human exposureandfollow-up. For 18 ofthe22 chemicals ex-
amined, thehuman evidence is consistent with thepredictions
based on the rodent bioassay results. For two chemicals, di-
chlorobenzidine and ethylene thiourea, there is not enough
epidemiological information tomake ausefulcomparison with
rodent bioassay data. The two chemicals for which thehuman
evidenceisinconsistent withthepredictions areactinomycinD
andvinylidenechloride. ButforactinomycinD, theconditions
ofthe rodentbioassay were inappropriate for thecomparison,
andforvinylidenechloridethehumanexposuredose was uncer-
tain; for either chemical future studies in humans might yet
demonstrate consistency with the rodent results (128).
RaVMouseChemicalCarcinogenicities
Ofthechemicalsthathavebeentestedinaninals, there arefew
for which reliable information as to human carcinogenicity
exists. Many more chemicals have been tested in two rodent
species, andhencethereis agreateropportunity forperforming
eitherqualitative orquantitativeinterspeciescomparisons ofcar-
cinogenicity. Most assays are performed in rodents, primarily
because oftheir relatively low cost, ease ofmaintenance, and
shortlifespan. Theirusemaybefortuitouslyappropriateinsome
cases. Inonestudyoftheefficacyofanimaltestsinthequalitative
(yes/no)predictionofhumantoxicityfor20chemicals, produc-
tionoftoxiclesionswasfoundtobetwiceaspredictivewhenthe
test species was the rat orthe mouseas it was whendogs were
tested, andlimiteddatashowedapproximatelythesamecorrela-
tionformonkeys as fortheserodent species (132). Also onthe
basisofcomparativetoxicology, ithasbeensuggestedrecently
thatthe results in rabbits mightextrapolatemoreaccurately to
humans thandoresultsinrats(14). Interspecies comparisons are
facilitatedwhenalltheanimaltestsareperformeduniformly. The
NCI/NTPtestsofrats, mice, andhamstersconformtoastandard
protocol and therefore lend themselves to such comparisons
(133,134).
Qualitative Comparison (Rat/Mouse)
Theconcordanceofpositive/negativeresultsforcarcinogen-
icity between rodent species has been examined by several
authors. The fraction concordant is defined as the number of
chemicalspositive(foratleastonesite)inbothspeciesplusthe
numberofchemicalsnegativeinbothspecies, dividedbythetotal
number ofchemicals tested. The NCI/NTP conclusions as to
carcinogenicity for 266 chemicals adequately tested in both
species were tabulated by Haseman and co-workers. With
equivocalresultsexcluded, 167/212(76%)wereconcordant(6,7).
Details ofthe correlations are reproduced from Haseman and
HuffinTable4. TheseresultsweresimilartothoseofPurchase,
who reported 82% concordance for a similar number of ex-
periments(135), manyofwhichwereincludedinthelaterstudy.
Byrdetal. reanalyzedthe raw dataoftheNCI/NTPdatabase.
Theyfoundthat76% oftheresultswereconcordantwhenweakly
significant (p < 0.025) dose-response trends were counted as
positive. Theyalsolookedathowwellpositivity/negativity for
benignormalignantmouselivertumorspredictsthepresence/
absence of a carcinogenic response in the rat at any site: the
overall concordance was 155/290 (53%) for benign liver ade-
noma and 165/290 (57%) for malignant liver carcinoma (8).
WhenalltheavailablebioassaydatatabulatedintheCPDB(not
limitedtotheNCI/NTPsubset)wasevaluatedwithrespecttothe
samecorrelation (formalignant andbenigntumorscombined),
Gold et al. (136) found a concordance of74/117 (63%). With
chlorinatedchemicals(definedascompoundsconsistingonlyof
C, H, Cl, and optionally 0) excluded, the concordance is
improved: 60/86 (74%).
Gold et al. also examined the overall positive/negative
agreement for carcinogenicity between rats and mice for the
Tlble4. Correlations in tumorresponsefor266NCI/NTP
carcinogenicity studies.'
Comparison +/+ +/- -/--/- Total % Concordant
Malerats/female rats 74 25 12 181 292 87.3
Males rats/male mice 46 43 36 145 270 70.7
Malerats/female mice 59 33 36 145 273 74.7
Femalerats/male mice 46 32 37 156 271 74.5
Femalerats/femalemice 57 23 39 156 275 77.5
Malemice/femalemice 78 10 23 177 288 88.5
Rats/mice (overall) 67 32 36 131 266 74.4
"DatareproducedfromHaseman andHuff(6). Equivocaloutcomeswerecon-
siderednegative.
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CPDB chemicals (136). Of the 392 chemicals tested in both
species, 226werepositiveinatleastonesex/species group; 76%
ofthe ratcarcinogens werepositive inthemouse, and75% ofthe
mouse carcinogens were positive in the rat. The overall con-
cordancewas 76%. Theircriteria forpositivity werethesameas
those ofHaseman and Huff(6). Experiments wereclassified as
positive only ifthis was the published opinion oftheauthor(s) of
the original study; all other experiments were classified as
negative. Noquantitativedose-response orpotency information
wasutilized. The predictivity ofthetenmostcommontargetsites
was also examined. Mostsites were found to begoodpredictors
ofcarcinogenicity at some site in the other species. The mouse
liver and the raturinary bladder/urethra werethe least accurate
predictors ofapositive carcinogenic response intheother rodent
species, and thepredictivity forthese sites is better forchemicals
that produce tumors at another site as well. Chlorinated com-
pounds weresignificantly lesspredictive thanothermouse liver
carcinogens: 45% (14/31) ofthosepositiveinmouse liverarepos-
itive in the rat, compared to 70% (60/86) ofother compounds.
The concordance between rats and mice for a "random"
sampleof25 chemicals drawn from the first 192 NCI bioassays
was assessed independently by three groups ofstatisticians as
part of a symposium on statistical problems; the results were
introduced and summarized by Young (137,138). The NCI had
previously declared 46% ofthe 25 chemicals to be positive for
carcinogenicity in at least one sex/species group, with 76%
agreement between rats and mice. All three groups ofstatisti-
cians evaluated the studies on a positive/negative basis for car-
cinogenicity; potency information was discarded.
The first analysis, the decision-tree approach ofSanathanan
et al., is the most satisfying on the basis of current biological
understanding and whatlogic tells us to expect forthe minimal
manifestations ofcarcinogenicity. They found anoverall agree-
mentof75% between ratsand mice fortumors atany site (139).
An even higher rate ofagreement (83%) was achieved in the
second analysis, by Louis, which combined dataover both sexes
and which included only malignant tumors (140). Several note-
worthy approaches to combining bioassay data were included,
although the author's Bayesian combination ofpotency informa-
tion from all chemicals is puzzling to us, since no adjustments
weremadeonthebasisofchemical structrueorpharmacokinetic
parameters.
The third analysis, by Bickis and Krewski, which is actually
four separatesub-analyses, was apparently conceived as ameans
ofpointing out to others what they ought not do (141). Three of
the authors' subanalyses rely onaggregatetumordata; inthe re-
maining one, their Decision RuleIII, data for specific lesions is
tabulated (which has been shown by several other studies cited
earlier to bethe better approach). When mock historical control
incidences were included, using Decision Rule III resulted in
96% (24/25) of the chemicals being found positive for car-
cinogenicity inboth species; the remaining chemical waspositive
in rats and inconclusive in mice. Therefore the agreement bet-
ween rats and mice was 100% (24/24). When historical in-
cidences werenotconsidered, then with this decision rule only
14ofthestudiesgaveadequateresults, andonly 6ofthese (43%)
were concordant in rats and mice. The authors make some in-
teresting inferences aboutfalse negatives, falsepositives, and the
pitfalls of using historical control data; none of the four sub-
analyses would be selected by anyone who, upon rational con-
sideration, isseriously intentupongetting themostreliable in-
formation out ofthe rodent bioassay. We emphasize thisjudg-
mentofoursbecausethefigureof96% positivityhasmisleading-
lybeenincludedintheabstractofanintroductiontothesepapers
(137), referring tothe "mostliberal" decisionruleofBickisand
Krewski (141), which those authors themselves surely would
neverrecommend. Theirfourdecisionrules werechosenasan
exercise in illustrating the inadequacies ofvarious simplifica-
tions, rather than as complete methods in themselves. Thus,
Young (137) has manufactured a huge inconsistency in the
analysis ofbioassaydata, especially withregardtothedecision
ofpositivity, where nonereally exists.
Hasemanhasrecently evaluatedtheentireanalytical exercise
indetail (142). Hepoints outthatonly very limitedinformation
wasavailabletothestatistical analysts: summarized site-specific
tumorincidences, survival rates, andsex. Allotherinformation
was withheld, including individual animal data, time-to-tumor,
the identity of the chemical compounds, dose levels, tumor
descriptions, andhistorical controldata. Thus, theanalysts were
forced to rely upon nonstandard methods, which were less
refined than whatare normally used (142). We notealso thatthe
results wouldhavebeen moremeaningful ifthebioassay data for
a much larger group ofchemicals, say the entire NCI data set,
had been subject to differential statistical analysis.
Quantitative Comparison (Rat/Mouse)
Many toxicologists have only considered a chemical to be a
potential humancarcinogen ifithascaused a significant number
oftumors intwo different animal species-usually rats and mice.
It is this set ofchemicals for which one performs quantitative
studies ofcorrelations between carcinogenic potencies in the two
species. This leaves open the question of the meaning of the
results of a bioassay in only one species, or bioassays in two
species where a statistically significant number oftumors was
found inonly one ofthe species. Is thechemical acarcinogen in
one species and a noncarcinogen (i.e., has zero carcinogenic
potency) in the other? Or is the failure to find evidence ofcar-
cinogenicity in the second species dueto the limited sensitivity
ofthe bioassay?
A statistical study cannot answer this question directly. But if
we reformulatetheproblem inmathematical terms then itcan be
more readily addressed. Webegin bypositing a model in which
the carcinogenic potency in speciesbcanalways bederived from
that in species a to within a certain accuracy, according to the
formula
lnfb = lna+ InKba+ E
where eis a random errorvariablegivenby
P(E)dE
= 1 xp 2 _2_ de
Then we ask, in those cases where a statistically significant
increase in tumors is found only in one species, does this con-
tradict the model?
Crouch and'Wilson took a qualitative argument, that the in-
duction of tumors at one site in one species is an indicator of
tumorigenicity at different sites in another species and made it
quantitative (39). They calculated maximum likelihood esti-
(3)
(4)
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FIGURE 4. Carcinogenic potency inB6C3F, mice versus F344 rats. (A) Dashed line isbestfitofdata shown. (B) Casesthat are not inevident agreement with the
dashed line of4A. From Crouch (37).
mates (MLE) of from NCI/NTP bioassay data, took the
geometric mean of the potencies at the most sensitive site in
males and females, andcomparedthesesex-averagedpotencies
for rats and mice. They found that thepotencies were inbetter
agreementifthecomparison wasbased onthemostsensitivesite
in each species than ifthe site was fixed. Crouchevaluated the
correlationanalytically using Eq. (3)andfoundthebestfitsolu-
tion fortheinterspecies conversion factorK between ratsand
mice (37). For 42% (78/187) of the chemicals there was a
statistically significant (p 0.025)tumorigenic responsein one
orboth species. Ofthese, 47% (37/78) were significantinboth
species; thecorrelation is shown inFigure4A. For 19 ofthe39
chemicals which produced a significant response in only one
species, the results were in self-evident agreementwithFigure
4A; results for the remaining 22 are shown in Figure 4B. As
before, the error bars encompass zero when the data are not
statistically significant. Although someofthe errorbarsdo not
touchthebestfitline(obtained fromtheexperimentswhich pro-
duced asignificant responseinbothspecies), thedeviation is not
large. Allthedata areconsistentwiththecorrelationgivenbyEq.
(3), with the error termdefined in Eq. (4), with achosen to fit
the data. In each case the error c in the correlation equation is
greater thanthe statistical uncertainty ofthe individual points.
Crouchshowedthatthere arefew cases, ifany, where one can
say definitively that a chemical is carcinogenic in one rodent
species and not in the other, based on the NCI/NTP bioassay
results (37). More precisely, he found that the carcinogenic
potency in onespecies is rarely morethan 100timeslessthanthe
potency inthe other. Metzger et al. broadened the scope ofthe
analysisby looking atbioassay dataotherthan thatobtainedby
the NCI/NTP program; approximately the same interspecies
(mouse/rat) correlation of minimum TD50 values (maximum
potencies) was found in both NCI/NTP and non-NCI/NTP
datasets (143). Rieth and Starr also found strong interspecies
(mouse/rat) correlations fora) maximum carcinogenic potencies
(1/TDSovalues) forchemicalsforwhichtheauthors' opinion was
positiveforcarcinogenicity, andb) upperboundpotencies(based
onlower-boundestimatesofTD50) forchemicalsforwhichthe
authors' opinion was negative with respect to carcinogenicity
(144). They foundweakerinterspeciescorrelations forthe cases
wherethechemical waspositiveinmicebutnotrats, orpositive
in ratsbutnotmice. It seemsto usthattheseresults areinaccord
withthoseofCrouch(37)andthatthecorrelationsdescribed are
consistentwiththehypothesisthattheinterspeciescomparison
ofpotencies is meaningful even for chemicals which produce
strongevidenceofcarcinogenicity inonly oneofthetworodent
species. However, RiethandStarrhave adifferentinterpretation.
They pointtothe interspecies correlationofMTDs as a source
ofbias (see below).
The findings ofCrouch and Wilson (39) were confirmed by
GaylorandChen (145); someoftheirresults arereproduced in
Table5. TheycomparedtheminimumTD5ovaluesinrats, mice,
andhamstersforallthechemicalsintheoriginalCPDB(129) as
a function of route of administration and tumor site. They
reportedthatthegeometric meanoftheratioformice/ratsis2.2
fordietand 1.13 for gavage. Whenthetumorsiteforbothspecies
wastheliver, thenthegeometric mean(mice/rats)is 1.48fordiet.
Inhalation gavethe poorest interspecies correlation. When the
route wasdiet, theratioofminimumTD5ovalues(mice/rats) was
distributed such that 73% (138/190) were between 0.1 and 10,
1.6% (3/190) weregreaterthan 100, and0.53% (1/190) wereless
than 0.01. Similar ratios were found for the hamster/rat and
hamster/mouse comparisons, although data was limited. The
authorsconcludedthatthevariation intheminimumTD30 values
acrossthethreerodentspeciesisgenerally within aflactorof 100
over a wide rangeofchemical compounds.
ChenandGaylor(146) usedtheCrumplinearized multistage
modeltofind the upperconfidencelimit onpotency(forthemost
sensitive site) atthelowestexperimentaldose for38 NCI/NTP
carcinogens; from the confidence limit they calculated the
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Tible 5 RatiosofminimumTD,)5 values (mg/kg-day), from
Gaylorand Chen (145).
No. of SD
Species Route Tumor site compounds Ratioa (log')
Mouse: rat Diet All 190 2.20 1.90
Mouse: rat Diet TBAb 33 2.22 1.58
Mouse: rat Diet Liver 16 1.48 1.61
Mouse: rat Gavage All 32 1.32 2.39
Mouse: rat Gavage TBAb 11 4.22 1.61
Mouse: rat Water All 10 0.69 2.42
Mouse: rat IP All 16 1.41 1.24
Mouse: rat IP TBAb 12 1.03 1.14
Mouse: rat Inhalation All 7 11.2 3.28
Hamster: rat Diet All 10 13.7 2.40
Hamster: mouse Water All 7 8.49 1.57
aRatioofgeometric means.
bTBA, tumor-bearing animals, any site.
estimated "virtually safe dose" (VSD), defined as that dose
which produces a cancer risk of 10 -6. For 69 same-sex
comparisons between B6C3Fj hybrid mice and rats of three
strains, theVSD ratios (rats/mice) varied from0.020to49, with
geometric mean 1.27andstandarddeviationln(6.23) = 1.83. The
ratios oftheminimumVSDvalues without regard to sexvaried
from0.021 to26, with geometric mean 1.37 and standarddevia-
tion ln(5.99) = 1.79. TheVSD ratio r was distributed such that
0.01 < r < 0.l for 12% (8/69), and 10 < r < 100 forthe re-
mainder (8/69).
Biases
Almost all experiments andcorrelations havebiases, anditis
important to discuss them. One obvious potential bias in the
interspecies comparison ofcarcinogenic potency isthat we nor-
mally lookonly atchemicals thathavebeen found toproduce a
statistically significant excess of tumors in both species. this
leaves open the question: Are there chemicals which are car-
cinogenic inonly oneoftwo species in which they weretested?
Ifsuchchemicalsexist, thenthecorrelationisobviouslylimited.
We addressed the question of the limit of sensitivity of the
bioassay by plotting the carcinogenic potencies in mice versus
those in rats, alongwiththe associated statistical uncertainty, in
Figure4. Theerrorbars showthatin everycase-thereis an upper
limit to potency, butthelowerlimitsometimes encompasses zero
(Figure4B). Fromthemagnitudeoftheuncertainties it was con-
cluded that for these examples, the occurrence of statistically
significant (p 0.025) evidenceofcarcinogenicity inonly one
speciesdid notprovideevidence ofexceptions tothecorrelation.
However, Figure 4 only indicates consistency withthe correla-
tion; itdoes not prove thatthe correlation is in factfollowed for
every chemical. Somechemicals couldbeexceptions totherule,
but it is not possible to tell.
There has been no systematic attempt, to our knowledge, to
study thebiases inthequalitative (yes/no) interspecies concor-
dance studies ofthe typeconducted by Haseman and Huff(6),
Gold etal. (136), andothers, inwhichcarcinogenicity isscored
on apositive/negative basis. Yetsimple arguments suggestthat
the biases will be greater than those for the quantitative com-
parisons. Asevidenced intheaboveparagraph, onevirtue ofthe
quantitative procedure is that itpermitsinterspecies comparison
ofchemicals positive in one species and nominally negative in
another (Fig. 4B). The qualitative interspecies concordance
studies are, ofnecessity, silentabout these cases.
As we have already noted, the experimental design of the
typical bioassay is such that, for most chemicals, the carcino-
genicpotency atthemostsensitive site isjustabovethe limitof
sensitivity. This meansthattheinterspeciesconcordanceofcar-
cinogenicity/noncarcinogenicity is very sensitive to thecriteria
forpositivity intheindividualbioassays. Recall thefourdecision
rules set down by Bickis and Krewski (141), the most conser-
vativeofwhichleadstoahighpercentageoffalsenegatives (the
assignment of non-carcinogenicity to chemicals that would
logically have been labeled as carcinogens under any set of
reasonable positive/negative criteria), and the most liberal of
whichleadstotheassignmentofpositivityin 100% ofthecases,
a large number ofwhich are false positives (chemicals ofvery
low or zero potency that would logically have been labeled as
noncarcinogens under any set ofreasonable positive/negative
criteria). Ifstatisticaldecisionrules forcarcinogenicity arenot
temperedbyjudicioususeofbiologicalinformation, theoutcome
is far less convincing than when all data, however untidy, is
allowedtoplayarole. Ontheotherhand, ifthedetailsofthere-
quirements forpositivity/negativity are notdecidedinadvance,
thereisenormouspotentialforbias(147). Afurtherbiasinposi-
tive/negativedecisionsenterswhentheexperimenterhasadesire
toprovethatachemicaliscarcinogenic. Themorebioassaysthat
arecarriedout, thegreaterbecomestheprobabilitythatonewill
produceasignificantly positiveoutcome, merelyduetochance.
Itisourcontentionthatbiasesinyes/noconcordancestudiescan
belargeineitherdirection,andthatthebestwayofstudyingthese
biases is by looking atthequantitative potency relationships.
Biasescanalsoappearinattemptstofindqualitativecorrela-
tionsbetweengenotoxicityandcarcinogenicity. Inastudyof73
chemicalstestedinrecentNCI/NTProdentbioassays, Tennant
et al. found that there was no complementarity between four
commonlyusedin vitrotestsforgenotoxicity (23). TheSalmo-
nella mutagenesis test had the highest specificity (negative
responseto nominal noncarcinogens) andthelowestsensitivity
(positiveresponsetocarcinogens). Theyconcludedthatnobat-
teryoftestsconstructedfromthesefourtestsofferedanimprove-
mentovertheSalmonellaassay. Sensitivitycouldbeimproved,
butthenspecificity wassacrificed. Furthermore, thethreemost
potent carcinogens examined were notpositive in any ofthe in
vitrotests. Asothershaverealized, ifachemicalisnegativeina
series ofshort-term tests having distinctgenotoxic end points,
further testing sometimes amounts to the experimenters' re-
lentlesspursuitofjustonepositivegenotoxicresponse. Ifenough
tests areattempted, thelawsofprobability, applied tothetests'
false-positive rate, make it likely that a positive result will be
found in some test.
That there is a good correlation between the carcinogenic
potencyatthemostsensitivesiteinratswiththatinmiceisnow
firmlyestablished, ashasbeenelaboratedinthisreview. Butthe
basis and relevance ofthis correlation has been the subject of
heateddiscussion. Inparticular, apaperbyBernsteinetal. (41)
has been misinterpreted frequently as providing an argument
againstthevalidityoftheinterspeciescorrelation. Hereweshall
endeavortoexplaintheresultsofthatpaper(quotingtheauthors
directly)andtheargumentitengendered. Mostofthefollowing
pointshavebeenmadepreviouslyby Zeiseetal. (148-150) and
Crouchetal. (42). Wehopethatourexpositoryeffortsherewill
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besuccessfulatclarifyingonceandforallourpositiononwhat
webelievehas beenproven and whathas not.
Bernstein et al. found that the best estimate ofb ofthe car-
cinogenic potency ((3) ofachemicaltested in a rodentbioassay
canbeapproximated asasimplefunctionofthemaximumdose
tested (MaxD). This may be written as
b =ln(qolq) (5)
MaxD
whereqois the fractionoftumor-freeanimals in thezero-dose
group, andqisthefractionoftumor-freeanimalsintheMaxD
group. Ifforratsandmiceinclusivethepossiblerangeofvalues
ofln(qolq) ismuch smallerthanthe rangeofMaxDvalues, and
ifthereis aninterspeciescorrelationbetweentheMaxDvalues,
thenEq. (5)impliesthattherewouldhavetobeanincidentalin-
terspecies correlation between the carcinogenic potencies as
well.
Bernsteinetal. didindeedfindagoodsame-sexcorrelationfor
MaxDvaluesbetweenratsandmicein 186NCIbioassays(41).
Asstatedabove, theMaxDisusuallyjusttheMTDoriscloseto
itinvalue, whiletheMTDisameasureofachemical'schronic
toxicity. Theexistenceofaninterspecies(rat/mouse)correlation
for acute toxicities (LD50 values) had already been described
(148,151).
Bernsteinetal. thenattempted toquantifytheexpectedvaria-
tion in ln(qolq) for an ideal two-group experiment in order to
predictthepossibleoutcomesofthecarcinogenicpotency (41).
In theirhypothetical scheme, thereare 50animals in each of2
dosegroups; thecontrolgroupreceivesdose = 0, thetreament
groupreceivesdose = d. Theyfurtherassumeda 10% incidence
oftumorsinthecontrolgroup(qo = 0.9)andreasonedthatthere
mustbeatleasta20% incidenceoftumorsinthetreatmentgroup
(q . 0.8) inorderthattherebeastatisticallysignificantincrease
in tumors. Initially, they allowed for the possibility of 100%
tumors (q =0). Withtheseentirely reasonablesimplifications,
Bernsteinetal. concludedthat "therangeofpossiblestatistically
significantestimatesof[(31 spans0.118/dtoinfinity." Thismeans
thattherangeofpossiblevaluesofln(qolq)isnotsmallcompared
to the rangeofMaxD values.
Butweknowthatonlyforafewchemicals(ofwhichethylene
dibromideisanexample)doesthefractionwithtumorsapproach
100% atanysite. Thisisafactofnature; ithasnothingtodowith
experimentaldesign. Thereisnoreasonwhythereshouldnotex-
istacarcinogen with lowtoxicity (high MTD), likesaccharin,
and high carcinogenic potency, like TCDD. Such carcinogens
may exist, but none has been found! We emphasizethat a car-
cinogen having these properties could readily bedetected in a
standardrodentbioassay; attheMTDitshouldyieldtumorsin
100% ofthe animals under test atthe most sensitive site.
Theoppositesituation, inwhichachemicalhashightoxicity
relativetoitscarcinogenicpotency, mayverywellexistbutwould
notbedetectedinastandardbioassay; attheMTDtherewould
notbe a significant increase in tumors. Ofchemicals tested in
animal bioassays, approximately halfare not found to be car-
cinogenic (6-8,31,136). These produce either no increase or
somenonsignificantincreaseintumorsattheMTD. Thefailure
ofthebioassay todetectthislattertypeofcarcinogenisimplicit
inBernsteinetal.'sanalysisofthehypotheticalidealexperiment:
therequirementthatqbelessthan0.8specificallyexcludesthem.
Bernstein et al., after noting the experimental absence of
chemicalswhichproduce 100% tumors,thengoontoexcludethe
possibility that such chemicals could appear (ifthey existed)
within the contextoftheir ideal two-group experiment. By ar-
bitrarily settinganupperlimitof98% (q 2 0.02)onthefraction
ofanimalsthatcouldpossiblygettumors, theupperlimitontheir
estimateofcarcinogenicpotencythenbecomes3.807/d. Taking
the ratioofupper(3.807kd) andlower(1.118/d) limits, they find
thatthestatistically significantvalues ofbcanvary only over a
32-foldrange. Butbyplacinganartificial upperlimit(98%)on
the possible fraction with tumors (and hence, onb), they have
biased theoutcome.
RiethandStarrexaminedthearithmeticrelationshipbetween
1/MaxDandthemaximumfinitevalueofcarcinogenicpotency,
O.,,U, for83carcinogenschosenfromtheCPDB(43). Howthese
particularchemicalswereselectedwasnotrevealed. Theyfound
thatthemeanofthedifference[(,,.- (1/MaxD)] was9.5 ± 2.2,
andthatthisdifferenceiscloselytiedtotherangeofdosestested
inthebioassay. ForvinylchlorideandTCDD,whichweretested
over200-foldand50-folddoseranges, respectively,thedifference
between(l3 and1/MaxDwasmorethananorderofmagnitude
largerthanthemean. Theauthorsconcludedthat"thedosestested
severelyandartifactuallyconstraintheestimatesofcarcinogenic
potencythatcanbederivedfromthemultistagemodel."
WeagreewithRiethandStarr(43)andBernsteinetal.(41)that
finitevaluesofflareconstrainedbyboththeMaxDandthedose
range.Buttheseworkersdidnottakeacarefullookatwhetherthe
relationship between the measured value of(3 and MaxD is
strongerthanwhatwouldbepredictedbasedontheseconstraints
alone.Weaddressthisquestionelsewhere(50),andreportthatfor
chemicalswithTD30 valuessignificantatp < 0.01,therelation-
shipbetween1/TD50andl/MaxDisweaker(haslargervariance)
formutagensthanfornonmutagens. Thefactthatthereexists a
significantdifferencedependinguponmutagenicity,whichisan
unrelatedvariable,suggeststhattherelationshipisindeedstronger
thanwhatisimpliedbytheconstraintsalone. Thereforeatleasta
portionofthecorrelationisnonspurious. Furthermore, wefound
thattheso-calledtwo-dose(zeroandMaxD)modelofBernstein
et al. does not approximate the actual distribution of(3 versus
V/MaxDcloselyenoughtobeusefulforexaminingartifactsinthe
apparentrelationshipbetweenthesetwovariables. Butwedidnot
ruleoutthepossibility, especiallyformutagens, thatthereislit-
tlemore(ornomore)quantitativeinformationtobegainedfrom
therelationshipbetweencarcinogenicpotencyandMTDthanis
alreadycontainedina)thestatisticalsignificancelevelatwhich
thepotency ischosen, andb)thefactthatchemicalsproducing
100%tumorsattheMTDarerare(SO). Figure 5,aplotofl/TD50
versus I/MaxDforchemicalstestedbytheNCI/NTPandwhich
producedastatisticallysignificantincreaseintumorsatanysite
inmice,isreproducedfromGoodmanetal. (SO);theoverlapbet-
weenmutagensandnonmutagens isself-evident.
Thereisasimilarpotentialbiasinthedirectcomparisonofcar-
cinogenicity inhumansandrodentsasperformedbyAllenetal.
(89). Thisarises due tothe factthat, for mostofthechemicals
whichtheyanalyzed, peoplewerealsoexposedathighdoses. In
occupational settings, exposurelimitsusedtobe setjustbelow
the level at which toxic effects were immediately obvious; to
reducethelevelsfurtherwasconsideredanunnecessaryexpense.
Chemotherapeuticdosesarealsoclosetothemaximumtolerated
level; lower doses are usually correspondingly less effective.
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FIGURE 5. Log-log plotofI/TD50 versus I/MaxD forNCI/NTP chemicals tested in mice. (X) mutagens; (O) nonmutagens. TD50values significant atp < 0.01.
From Goodman et al. (50).
Therefore, any argument that the correlation ofcarcinogenic
potencies formiceand rats is aspurious consequence ofthe cor-
relationoftoxicdoseswouldlikewiseapply tothecorrelationof
carcinogenic potencies for rodents and humans.
Another bias relates to the choice ofchemicals for testing in
rodent bioassays. The relative ease of in vitro testing for
mutagenic andothergenotoxicactivitymakes itunlikely that any
new chemical willbeconsidered for massproduction ifitturns
out to be genotoxic. Consequently, fewer new carcinogenicity
bioassays areperformed onchemicalsthat aregenotoxic in any
ofthe standard in vitro tests.
Undoubtedly, there are other biases that have not been iden-
tified. However, webelievethatitisalready clearthat astudyof
the interspecies correlation factorKcannotbe separated from a
study of the relationship between toxicity and carcinogenic
potency, oroftherelationshipbetweencarcinogenic potencyand
activities atthecellularlevel(includingcytotoxicityandgenotox-
icity). We agree with Clayson(152,153) andothers who declare
thenecessity toimprovethecarcinogenriskassessment process
by increasing and utilizing ourunderstanding ofthe biological
mechanisms ofcarcinogenesis.
Genotoxic Versus Nongenotoxic
Agents and the Rodent Bioassay
Recently, Ashby and Tennant, expanding upon and corrobor
atingtheworkofTennantetal. (154), foundthatthedistribution
of tumor sites for agents mutagenic to Salmonella is different
fromthosewhich are not(76). They examined222carcinogens
whichhadbeentestedbytheNCI/NTPinbothmiceand rats. If
achemical wasfoundtobemutagenic inSalmonellaandalsohad
certain structural attributes which have been associated with
mutagenicity (155), it wasclassified bytheseauthors asgenotoxic
(+/+). If negative in both, it was classified as nongenotoxic
(-I-). The +/+ chemicals produced all tabulated tumors ex-
cept for seminal vesicle, cholangioma, urinary tract, and lym-
phatic system. The -/- carcinogens were more restricted in
their range,producing tumors atonly 15ofthe31 tabulatedtumor
sites. Benzene, which is apotentgenotoxin in most in vitro and
in vivoshort-termtests, nevertheless failsto inducepoint muta-
tions intheSalmonella assayanddoes nothave anyofthe struc-
tural featuresidentifiedbyAshby (155) aspredictiveofmutagen-
icity. Thus, benzene is -/- bytheabovecriteria, butAshby and
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Tennant do not include it in the analysis oftumor site distribu-
tion because to do so would mask the site differences between
truly nongenotoxic carcinogens and genotoxic carcinogens. The
liver was the most common target site for both+/+ and -/-
carcinogens, buta-/- carcinogen was approximately twiceas
likely as a +/+ carcinogen to cause liver tumors. Of those
chemicals which caused tumors only in the mouse liver, 70%
were not mutagenic in Salmonella. These findings concerning
mouse liver tumors were in general agreement with those of
Ward et al. (156).
The Science Advisory Board ofthe U.S. Environmental Pro-
tection Agency (EPA) spent a day in August 1987 discussing
whetherornotinductionofmouselivertumors (andforanother
reason, rat kidney tumors) provides sufficient evidence that a
chemical is a complete carcinogen. One widely held view was
that chemicals which produce only mouse liver tumors, par-
ticularly inthemaleB6C3F, mouse (which has ahigh natural in-
cidenceoflivertumors andelevated peroxisome levels compared
to females and to other strains), may be acting as tumor pro-
moters ratherthanascompletecarcinogens. Thathepaticperox-
isomeproliferators also inducehepatocellularcarcinoma is well
known (157). The paper by Ashby and Tennant indirectly cor-
roboratestheview thatmostcarcinogenswhi-charespecific for-
mouseliverarenotprimary carcinogens, and thatthey may act
instead topromote thedevelopmentofneoplasms inpre-initiated
cells (76). Gold et al. also found such a distinction: for the.91
mouselivercarcinogens whichhadbeentested formutagenici-
ty in Salmonella, 32% (8/25) ofthe single-site carcinogens are
mutagenic, compared to 56% (37/66) ofthe multiple-site car-
cinogens. Butacontradictory note is struck by the observation
thatforthe20NCI/NTPchemicalswhicharesingle-siteB6C3F,
mouse liver carcinogens, tumorigenicity is not strongly cor-
related with sex: 13 producetumors inboth sexes, 5 inthe male
only, and2 inthe femaleonly (136). Aneven weakercorrelation
with sex was previouslyfound for26 single-siteB6C3F, mouse
liver carcinogens by a group ofNTP scientists (158).
The most important conclusions ofAshby and Tennant (76)
werethat"screening chemicals forgenotoxicity usingstructural
analysis andaminimum numberofgenotoxicity assays, anduse
ofa reducedcancer bioassay protocol, would enable the detec-
tionoftrans-species/multiple-site rodentcarcinogens. Thedetec-
tion of tissue/sex/species-specific carcinogens can only be
achieved by conducting life-time carcinogenicity bioassays ac-
cording to the present NTP protocol."
Regulatory Demands and Paradoxes
Thefactthatabouthalfofthechemicalstested inrodents pro-
duce statistically significant tumor increases has important
regulatory consequences. Itis no longerpossible tohavea "ban
them all" approach. Many synthetic and naturlly occuring
chemicals which havesomemeasurablecarcinogenic activity are
important in everyday life. Chloroform is formed in drinking
water from the reaction of chlorine (added to curb bacterial
growth) withorganiccontminants presentinmostpublicwater
supplies. TheEPA faces theparadox that itis forced to accept a
maximum contaminant level (MCL) for chloroform in public
water systems of 100 ppb (159), yet the MCL goal for tri-
chloroethylene is set at zero (160), even though the latter
chemical isanorderofmagnitude lesspotentacarcinogen than
chloroform. TheU.S. FoodandDrugAdministration (FDA) and
theEPAtogetherpromulgate inconsistencies intheirattemptsto
limithumanexposuretocarcinogens; theFDAacceptspeanutbut-
terwith20ppbtotalaflatoxins(includingB1)andhaveproposed
thatthetolerancebeloweredto 15ppb(16I),eventhoughaflatoxin
B1 isatleast 10'timesmorepotentthantrichloroethylene.
The EPAjustifies its useofthe surface area correction factor
(which theFDAdoes notuse)onthegroundthatitismore "con-
servative." Wedo not contest thisdesire to be conservative, but
suggest that the factors beexplicitly included. We have argued
that Kshould beunity within anuncertainty factor of20 either
way(52). Ifit is desired to beconservative, onemay take20,so
long asitisclearlyrecognized thatthere aremany chemicals for
which this ishigh. It should also be recognized that for many
chemicals Kwould be 1, for some Kwould be 1/20, and for any
untested chemical Kmay approach zero.
Theinterspeciespotency factors discussed here are intended
tobeusedinnumerical riskestimates. Itmustberecognized that
manydistinguished scientistsdo notaccepttheuseby ourselves
andbygovernmentagencies ofnumerical values for interspecies
factors incalculating a risk. For example, Ames et al. use the
term"possible hazard" for estimates ofhuman carcinogenicity
based on rodent bioassays and do not write the word "risk"
unless data is available from human exposures (4). They pro-
ducedahumanexposuredose/rodentpotency dose (HERP) in-
dex, in which the human lifetime daily dose is expressed as a
percentageofthe rodentTD50, whereboth are inunits ofmg/kg-
day. For K = 1, the HERP dividedby100/ln(2) becomes what
wewouldcalltherisk, andtheorderofchemicals listedby HERP
valueisthe sameas iftheywerelistedby risk. Inthetext, Ames
etal.usetheirlisttosuggestthatexposuresassociatedwithasmall
HERPvaluecanbeignoredcomparedto substanceswithalarger
one. ThisusecanonlybevalidifitisassumedthattheHERP in-
dexisrelatedtorisk. Thusalltheassumptions, restrictions, and
qualificationsappropriatetotheinterspeciescomparison ofcar-
cinogenicpotencies alsoapply wheneverthe HERP isused.
Doll and Peto emphasized the uncertainty in quantitative
estimation ofhuman risk from animal data and suggested that
"priority setting" should replace "risk assessment" (84).
Specifically, they recommended that a chemical's potency in
each test (including long-term carcinogenicity bioassays and
short-term invitrotests) bemultipliedbyanestimate ofhuman
exposuretoyieldanindexofhumanhazardaccording tothatone
test. Chemicals thatappearedhigh onany index would be con-
sideredprime candidates forregulatory action. One appealing
aspectofthis recommendationisthatitinsures thatnochemical
which ispotentbyany criterion isoverlooked. We note that the
above-mentioned indexofAmes etal. isanexample ofthe pro-
ceduresuggestedby DollandPetowhenthetestunderconsidera-
tion is the rodent bioassay.
Suggestionsfor Future Work
An important issueconcerning high-dose/low-dose extra-
polationmightberesolvedbycarefuldocumentationofthedose-
responseforcellproliferation. Ifitistruethatcellproliferationis
responsible forcarcinogenicity attoxicdoses, asis now widely
believed,thenacorollaryhypothesisisimmediatelyapparent: that
chemicals which are notgenotoxic in agiven target organ and
whichdonotcauselocalcellproliferationwillnotcausecancer
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inthatorgan. Thisisapowerfulnotion; onewithunprecedented
power to change the faceofcarcinogen risk assessment.
Wewishtoemphasizetheneedforadequaterodentbioassays,
inwhichtherouteofadministration ismatchedtothehumanex-
posureroute, forchemicalsalready knowntobecarcinogenic to
humans. Intheabsenceofgoodanimaldataforallknownhuman
carcinogens, refinement of the methodology for predicting
potency in humans from potency in animals is seriously hin-
dered. Likewise, thereisadearthofknowledge astothepoten-
cies of known human carcinogens. For some chemicals, the
necessary quantitative informationcouldbederivedfromcom-
pleted or ongoing epidemiological studies. Ifepidemiologists
could be persuaded of the importance of obtaining potency
estimates, then more studies would bedesigned so as to reveal
theeffectsatdifferentexposurelevels. Inthoseepidemiological
studies inwhichnostatistically significantincreaseinneoplasms
arefound, weencouragethedeterminationofupperlimitstocar-
cinogenic potency.
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